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Prediction of chemical bioactivity and physical properties has been one of the most important applications
of statistical and more recently, machine learning and artificial intelligence methods in chemical sciences.
This field of research, broadly known as quantitative structure–activity relationships (QSAR) modeling, has
developed many important algorithms and has found a broad range of applications in physical organic and
medicinal chemistry in the past 55+ years. This Perspective summarizes recent technological advances
in QSAR modeling but it also highlights the applicability of algorithms, modeling methods, and validation
practices developed in QSAR to a wide range of research areas outside of traditional QSAR boundaries
including synthesis planning, nanotechnology, materials science, biomaterials, and clinical informatics.
As modern research methods generate rapidly increasing amounts of data, the knowledge of robust data-
driven modelling methods professed within the QSAR field can become essential for scientists working both
within and outside of chemical research. We hope that this contribution highlighting the generalizable
components of QSAR modeling will serve to address this challenge.
Introduction
Quantitative structure–activity relationship (QSAR) modeling
is a well-established computational approach to chemical data
analysis. QSAR models are developed by establishing empirical,
linear or non-linear relationships between values of chemical
descriptors computed from molecular structure and experi-
mentally measured properties or bioactivities of those mole-
cules, followed by application of these models to predict or
design novel chemicals with desired properties.
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Historically, QSAR modeling has been largely applied to
computer-aided drug discovery. Many papers, reviews, and
book chapters describing the methods and applications of
QSAR modeling have appeared in the scientific literature since
the seminal publication by Hansch et al. in 19621 that effec-
tively pioneered the field. More than five years ago, some of the
contributors to this paper co-authored a comprehensive review
of QSAR modeling,2 where we discussed the evolution of
methods and best practices of QSAR. Since then, the field has
grown and evolved substantially. The Web of Science core
collection lists more than 5600 papers on QSAR published
within last five years, a substantial fraction of the B20 000
papers that have been published on this subject since 1962.
Many publications have advanced the traditional areas of QSAR
modeling3 such as prediction of biological activities and ADME/
Tox properties, building on successful use of QSAR modeling
in chemical, agrochemical, pharmaceutical,4 and cosmetic
industries.5 However, new and interesting directions and appli-
cation areas have also emerged, such as process chemistry6,7
and (retro)synthetic route prediction and optimization.8 Thus,
models have become an integral component of the drug
discovery process, providing substantial guidance in planning
experiments.4,9
In cheminformatics molecules are represented by mathe-
matical descriptors that encode molecular structures and prop-
erties. Multivariate statistical methods or machine learning are
employed to establish relationships between descriptors and
a target property, such as molecular bioactivity. It is easy to
see that analogous representations can be generated for many
types of data where objects are represented by their features, and
the general objective is to predict object properties (endpoints)
from these features. For instance, in clinical data, the objects
would be patients, the features would be clinical or pharmaco-
logical biomarkers characteristic of the patients, and the target
property would be the any health outcomes such as the rate of
patient survival.
Regardless of the nature of the data, the same machine
learning (ML) approaches can be used universally to analyze
and process data in any domain. Furthermore, despite differences
in the information content and meaning of the data, different
research fields share similar data handling routines. These often
replicate the workflows and protocols already created, evaluated,
and used in QSAR. Indeed, the general data cycle associated with
QSAR projects (Fig. 1) can be easily adopted for similar data-
analytical investigations in other fields. To further illustrate this
point, Table 1 provides a collection of recent references describing
studies in diverse research areas that cite some or many concepts
from QSAR. Examples include fields as diverse as climatology,10
urban engineering,11 student admissions,12 remote sensing13 and
clinical informatics (discussed in one of the sections of this
contribution). Importantly, QSAR modeling was among research
fields that relatively early highlighted such subjects as the impor-
tance of data curation,14 rigorous validation of developed
models,15 and data reproducibility,16 that have recently become
a significant concern to the general scientific community.17
Here we integrate contributions from some of the leading
experts in QSAR modeling that illustrate the breadth and
generality of modern data processing and modeling practices
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in the field and highlight the applicability of these methods
outside of the traditional borders of the field.18 The contributors
have worked both on methodology and applications of QSAR
modeling for most of their professional life. Some of the
co-authors have pivoted their research into other areas where
QSAR-like approaches have not been used before, illustrating the
main theme of this paper by their own careers. We engaged other
scientists who work in areas where data modeling was not
common but who have started using QSAR-like methods in their
research. We are confident that many fields that employ statis-
tical modeling approaches will benefit significantly from the
experience accumulated within the QSAR community in the last
55 years.
We start this contribution by discussing fundamental concepts
of QSAR, such as chemical similarity. We describe the impact of
recent advances, such as deep learning (DL), on traditional areas
of QSAR modeling, such as drug discovery and development and
chemical safety prediction. We then reflect how the complexity of
algorithms and the size, diversity, and complexity of chemical
bioactivity data have grown. We also illustrate how modern
computational methods are capable of modeling multiple
bioactivity endpoints simultaneously, addressing the issue
of multi-objective optimization. We then extend traditional
boundaries of QSAR by summarizing recent, exciting develop-
ments in organic synthesis planning and retrosynthetic path-
way prediction, advances in robotic chemistry, and applications
of machine learning to quantum chemistry. Finally, to further
illustrate the breadth of applicability of modern QSAR appro-
aches, we discuss their use in materials and nanomaterials
science, regenerative medicine, and health care. Throughout
the discussion, we identify methodological similarities between
drug discovery approaches and those employed in other areas.
We further propose that experience and best practice of data
curation, model development, and validation accumulated by the
QSAR community provides valuable guidance for many areas
where statistical and machine learning data modeling is applied.
This broad, platform applicability of QSAR algorithms and
protocols across all data-rich areas of modern science under-
pins the appeal of QSAR as a robust, predictive data analysis
and modelling tool. We advise contemporary chemists to
become familiar with the major computational approaches
discussed in this contribution. To this end, borrowing from a
recent ‘‘In the Pipeline’’ blog by Derek Lowe,19 ‘‘it is not that
machines are going to replace chemists. It’s that the chemists who
use machines will replace those that don’t’’! We hope that this
paper will stimulate experimental scientists to consider deeper
integration of computational methods and models into their
research projects, to consider how the data they generate will be
modelled when planning experiments and will serve as useful
reference for computational chemists as well.
Clearly, QSAR modeling is an established and useful com-
putational chemistry approach. However, many practitioners
Fig. 1 Data cycle associated with QSAR modeling projects.
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Table 1 Examples of QSAR-‘‘inspired’’ studies from diverse research areas
Cited paper Title Journal Year/ref.
315 Sensory analysis of red wines: Discrimination by adaptive fuzzy partition Journal of Sensory Studies 2008/318
15 Improved wheat yield and production forecasting with a moisture stress
index, AVHRR and MODIS data
Crop and Pasture Science 2009/319
15 Use of genetic algorithm and neural network approaches for risk factor
selection: A case study of West Nile virus dynamics in an urban
environment
Computers Environment and Urban Systems 2010/11
15 Whole cell-catalyzed transesterification of waste vegetable oil Global Change Biology Bioenergy 2010/320
15 New Ground-Motion Prediction Equations Using Multi Expression
Programing
Journal of Earthquake Engineering 2011/321
322 Qualitocracy: A Data Quality Collaborative Framework Applied to Citizen
Science
IEEE Conference Proceedings 2012/323
15 Gene expression programming as a basis for new generation of
electricity demand prediction models
Computers and Industrial Engineering 2014/324
315 Development of a model for quality evaluation of litchi fruit Computers and Electronics in Agriculture 2014/325
15 and 315 Good practices in LIBS analysis: Review and advices Spectrochimica Acta Part B-Atomic Spectroscopy 2014/326
327 Characterization of Softwood and Hardwood LignoBoost Kraft
Lignins with Emphasis on their Antioxidant Activity
BioResources 2014/328
315 Gene expression models for prediction of dam breach parameters Journal of Hydroinformatics 2014/329
315 An entrainment model for non-uniform sediment Earth Surface Processes and Landforms 2015/330
15 Indirect estimation of the ultimate bearing capacity of shallow foun-
dations resting on rock masses
International Journal of Rock Mechanics
and Mining Sciences
2015/331
15 A novel protocol for assessment of aboveground biomass in
rangeland environments
Rangeland Journal 2015/332
15 Statistical Modeling of Soil Moisture, Integrating Satellite
Remote-Sensing (SAR) and Ground-Based Data
Remote Sensing 2015/13
315 Testing and Prediction of Material Compatibility of Biofuel
Candidates with Elastomeric Materials
International Journal of Fuels and
Lubricants
2015/333
315 Regression Algorithms in Hyperspectral Data Analysis for Meat Quality
Detection and Evaluation
Comprehensive Reviews in Food Science
and Food Safety
2016/334
315 Evolutionary patterns and physicochemical properties explain
macroinvertebrate sensitivity to heavy metals
Ecological Applications 2016/335
315 Restricted attention to social cues in schizophrenia patients European Archives of Psychiatry and Clinical
Neuroscience
2016/336
322 Molecular descriptor data explain market prices of a large
commercial chemical compound library
Scientific Reports 2016/337
15 A hybrid intelligent fuzzy predictive model with simulation for supplier
evaluation and selection
Expert Systems with Applications 2016/338
315 Development of a stage-dependent prognostic model to
predict psychosis in ultra-high-risk patients seeking treatment
for co-morbid psychiatric disorders
Psychological Medicine 2016/339
315 Prediction of Timing of Watermain Failure Using Gene Expression
Models
Water Resources Management 2016/340
15 A new approach for modeling of flow number of asphalt mixtures Archives of Civil and Mechanical
Engineering
2017/341
15 Next generation prediction model for daily solar radiation on
horizontal surface using a hybrid neural network and simulated
annealing method
Energy Conversion and Management 2017/342
322 Computer-Assisted Decision Support for Student Admissions
Based on their Predicted Academic Performance
Journal of American Pharmaceutical
Education
2017/12
315 Predicting Bond Strength between FRP Plates and Concrete
Substrate: Applications of GMDH and MNLR Approaches
Journal of Advanced Concrete Technology 2017/343
15 Gene Expression Programming Approach to Cost Estimation
Formulation for Utility Projects
Journal of Civil Engineering and
Management
2017/344
315 Prediction of flow duration curves for ungauged basins Journal of Hydrology 2017/345
15 Maize [Zea Mays (L.)] crop-nutrient response functions extrapolation
for Sub-Saharan Africa
Nutrient Cycling in Agroecosystems 2017/346
15 Performance assessment of existing models to predict brittle failure
modes of steel-to-timber connections loaded parallel-to-grain with
dowel-type fasteners
Engineering Structures 2018/347
315 A comparative study on groundwater spring potential analysis based on
statistical index, index of entropy and certainty factors models
Geocarto International 2018/348
349 Environmental factors influencing snowfall and snowfall prediction in
the Tianshan Mountains, Northwest China
Journal of Arid Land 2018/350
15 and 315 Prediction of riprap stone size under overtopping flow using
data-driven models
International Journal of River Basin
Management
2018/351
15 Forecasting experiments of a dynamical–statistical model of
the sea surface temperature anomaly field based on the
improved self-memorization principle
Ocean Science 2018/10
315 Expressed emotion as a predictor of the first psychotic
episode – Results of the European prediction of psychosis study
Schizophrenia Research 2018/352
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still consider it limited to modeling and prediction of chemical
bioactivities and/or properties. One aim of this Perspective is to
outline the opportunities presented by recent and emerging
developments in artificial intelligence (AI), machine learning
(ML) and other approaches to modeling Big Data within the
traditional QSAR modeling. However, our prime objective is to
emphasize the impact that QSAR methods and approaches
have, or will shortly have, on many modern data-driven areas
of molecular research beyond traditional QSAR areas. We called
this paper QSAR without borders, to emphasize the plausible
impact that many data modeling approaches developed and
practiced by the QSAR community may have on many areas of
the scientific pursuit.
Chemical similarity
Classical QSAR is defined by linear (regression) models derived
from a set of small molecules sharing the same (target-specific)
biological activity. A QSAR model predicts changes in potency
as a function of structural modifications.1,20 The evolution of
QSAR modeling from linear to more complex machine learning
models addressing non-linear relationships between chemical
structure and bioactivity was discussed in a paper co-written by
one of the founders of classical QSAR, Prof. Toshio Fujita in
2016.20 Chemical bioactivity data employed in model develop-
ment are generally derived from investigations of analog series
from medicinal chemistry. These sets of compounds usually
share a common core structure (scaffold) and carry different
substituents (R-groups) at one or more sites. Descriptor-based
linear regression models then predict potency of newly
designed analogs to further extend such congeneric series, a
fundamental task of classical QSAR. This prediction scheme is
provides a useful guide to compound design and synthesis,
making QSAR one of the most popular predictive approaches in
medicinal chemistry since its seminal development.1
QSAR modeling is based upon the premise that structurally
similar compounds exhibit similar biological effects, often
referred to as the similarity-property principle (SPP). The SPP
postulates a conceptual link between molecular similarity
and biological activity and implies that gradual changes in
compound structure are accompanied by gradual changes in
potency, which provides a rationale for the derivation of linear
QSAR models. In congeneric series, analogs share the same
core, which renders them similar. R-group replacements result
in incremental changes in structure and ensuing potency
variations should be predictable. The applicability domain of
these predictions is defined by the SPP and requires the
presence of ‘‘SAR continuity’’,21 as illustrated in Fig. 2.
Chemical similarity is often evaluated in relation to bio-
activity. Multi-dimensional structure–activity relationship (SAR)
landscapes derived from models, describe similarity relation-
ships between active molecules and their biological potency
differences. These can be used to understand the effects of
various structural features on biology, especially SAR continu-
ities versus discontinuities in compound responses.22 SAR
continuity is directly associated with the SPP, implicating a
smooth continuous relationship between conservative structural
modifications of active compounds and accompanying moderate
potency alterations. In contrast, SAR discontinuities21 occur when
Fig. 2 SAR characteristics of cyclooxygenase-2 inhibitors. Substitutions are highlighted. For each compound, the pIC50 value is reported.
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small structural modifications lead to very large biological potency
changes, not consistent with the SPP and falling outside the
applicability domain of linear QSAR models. Fig. 3 shows small
sets of active compounds that are characterized by SAR continuity
and discontinuity, respectively. ‘‘Activity cliffs’’ are formed by
analogs displaying the largest potency differences in a compound
series for the smallest change in structure.23 The existence of
activity cliffs in compound data sets is a major factor limiting
QSAR predictions, often much greater than intrinsic limitations
of modeling.23 Strikingly similar observations have also been
made in bioinformatics where some pairs of proteins with high
sequence similarity possess very different structures and
functions.24 This analogy is one of many that methodologically
bridge between QSAR and other fields that rely on data analytics.
It should be noted that activity cliffs may be sensitive to both
the choice of descriptors and the degree of the experimental
variability. Importantly, SAR discontinuity limits QSAR modeling
regardless of molecular representations and descriptors that are
used when the corresponding compounds are close structural
analogs. Activity landscapes of compound data sets might be
‘‘flattened’’ by using large numbers of features as molecular
representations such that compounds become increasingly dis-
similar (i.e., their distances in feature space increase). However,
introducing artificial dissimilarity results in a loss of SAR informa-
tion (and often leads to overfitting of regression models).
In QSAR modeling the presence of SAR continuities and
discontinuities in sets of active compounds is not mutually
exclusive. Rather, continuous and discontinuous SARs coexist
in many data sets21 resulting in the presence of adjacent gently
sloped and rugged regions in activity landscapes (Fig. 3).
Focusing potency predictions around local regions of SAR
continuity can often lead to QSAR models with high predictive
power. To this end, numerical SAR analysis methods can
be used to identify compound subsets having desirable SAR
characteristics.25 Numerical similarity in QSAR is mostly quan-
tified using the Tanimoto coefficient or related similarity
metrics, which provide continuous similarity values, typically
in the interval [0,1]. Numerical measures assess whole-molecule
similarity on the basis of chosen descriptors. For larger com-
pound sets, Tanimoto similarity calculations are often carried out
using molecular fingerprints,26 especially in machine learning.27
Different from numerical similarity measures, substructure-
based approaches yield a binary readout of similarity,
i.e., either two compounds are classified as similar or not.
A standard approach in substructure-based similarity assess-
ment is clustering of compound data sets on the basis of
hierarchical scaffolds extracted from them.28 Such scaffolds
are conventionally used to represent core structures. In addition,
substructure-based similarity can be assessed by calculating
the maximum common substructure (MCS) of compounds,
although MCS calculations are typically only meaningful for
small compound sets.29 By contrast, similar to scaffold analysis,
substructure-based similarity can be determined on large scale by
applying the matched molecular pair (MMP) formalism. An MMP
is defined as a pair of compounds that are only distinguished by a
chemical modification at a single site.30 Accordingly, compounds
forming an MMP contain a common core and the distinguishing
chemical modification can be rationalized as the exchange of a
pair of substructures, termed a chemical transformation. Algo-
rithms for MMPs generation are highly efficient.31 By limiting the
size of transformations, it is readily possible to restrict formation
of MMPs to pairs of analogs.32 By combining MMP search with
network analysis, analog series can be systematically extracted
from large compound sets and subjected to SAR exploration and
QSAR modeling.33
Going beyond the traditional QSAR paradigm means depart-
ing from the SPP. Modeling compounds with increasingly
diverse structures with few or no common scaffolds means that
structural differences between active compounds are not gra-
dual, such as those that arise from ‘‘scaffold hopping’’.34 This
leads to structurally diverse active compounds that require non-
linear approaches to modeling SARs satisfactorily, making
bioactivity predictions more difficult. Non-linear SAR models
require analysis of relationships between structure of both
close and remote structural analogs and respective changes in
their potency. This is beyond the capacity of classical linear
regression QSAR methods and generally requires the use of
machine learning (ML) as discussed in the next section.35
To summarize, the choice of molecular representations
(descriptors) and assessment of molecular similarity play a
critical role in QSAR.36 It should be emphasized that compar-
ison of object representations, their similarity metrics and the
interplay between object relationships and associated (latent)
properties is of general relevance for data modeling irrespective
of research areas. In fact, the similiar similibus curantur (‘‘likes
are cured by likes’’) principle formulated by Paracelsus37
(the ‘‘father of toxicology’’) could be seen as one of the most
common ways of rational thinking (reflected in the SPP principle as
applied in cheminformatics) and reasoning approaches in nearly
any area of science. As highlighted throughout this contribution,
this principle is one of key drivers of the general applicability of
approaches and tools employed in cheminformatics.
Modern trends in QSAR modeling
Chemical similarity may help with qualitative assessment of
compound bioactivity but its quantitative evaluation requires
the use of statistical tools that can model the relationship
between chemical structure and bioactivity.1 Currently, there
is much talk about the use of artificial intelligence (AI) in
chemistry. Here we distinguish between AI and machine learning
in the following way. AI is the superset of tasks that demonstrate
characteristics of human intelligence, while ML is a subset of AI
which accesses data, analyses trends and generates intelligent,
actionable insights. Many people use the term AI in the same
context as ML in many data-rich disciplines, ranging from health
care to astronomy. In this regard one can say that AI has been
used in chemistry since the 1960’s under the name QSAR.
In general, ML represents a set of techniques for predicting a
property Y based on known examples, where each example i has
property Y(i) and a set of k features X(i,j), j = 1 to k. In this section
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/3
0/
20
20
 1
0:
15
:5
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2020 Chem. Soc. Rev., 2020, 49, 3525--3564 | 3531
we show how QSAR modeling can be applied much more broadly
than has been the case previously. Theoretical organic chemistry,
a highly specialized field, gave rise to the QSAR paradigm. The
experience and trends in modern QSAR we summarize in this
section is illustrative, and perhaps, instructional, for any data-rich
area of research.
Machine learning suffers from the same philosophical lim-
itations that any type of inductive learning does: distinguishing
correlation from causation and knowing when we have enough
training examples to generate a model that makes accurate
predictions for new cases, etc. In QSAR, the dependent variable
Y is usually some biological or physical property, and the
independent variable features X (called ‘descriptors’ in
chemical applications) are derivable from chemical structures.
In QSAR, historically the objects are drug-sized molecules, but
that is not always the case. Objects can be atoms, protein
sequences, pairs of proteins, etc., so long as relevant descriptors
can be generated.
Chemical descriptors for drug-sized molecules fall into two
main categories: substructures, which note the presence and/or
frequency of certain groups, and computable properties that
are representative of the entire molecule. In QSAR, the function
that maps Y from X is called a model. Obviously, the same
general construct is used in statistical modeling in any field,
Fig. 3 Different SAR patterns. Shown are inhibitors of tyrosine kinase ABL forming different SARs. For each compound the logarithmic potency (pKi)
value is reported. At the top, SAR continuity is observed where gradually changes in compound structure (traced by horizontal arrows) are accompanied
by moderate potency alterations. By contrast, the inhibitors at the bottom display SAR discontinuity. Here, small structural modifications lead to large
changes in potency. Vertical arrows indicate the formation of pairwise activity cliffs.
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/3
0/
20
20
 1
0:
15
:5
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
3532 | Chem. Soc. Rev., 2020, 49, 3525--3564 This journal is©The Royal Society of Chemistry 2020
except the nature of descriptors depends on the type of the
objects.
This section concentrates on trends in QSAR in the pharma-
ceutical industry because, arguably, that is where the opportu-
nities and challenges for innovation and potential impact on
society are greatest.38 Most pharmaceutical companies are
likely to develop QSAR models for on-target (e.g., binding of
ligands to targets) and off-target (secondary pharmacology)
activities, as well as ADMET (absorption, distribution, meta-
bolism, excretion, and toxicity) properties, which are discussed
in the next section. Companies also develop their own best
practices for building and using QSAR models. Models are used
so that predictions can substitute for experiment under some
circumstances. However, the current state of the art in QSAR
modeling often precludes chemists from relying fully on indi-
vidual quantitative predictions. Instead, the proper application
of QSAR is the prediction of trends, which are accurate enough
to prioritize sets of compounds for synthesis and experimental
evaluation.
Researchers are always seeking ways to improve their science,
and the field of QSAR is no exception. There are many recent
trends but here we describe the most important ones that in our
opinion, can be generalized to many other research fields:
1. Data. Data driven modeling methods are clearly highly
dependent on data size, quality, and diversity.39 The size and
diversity of datasets have dramatically increased in recent years
due to technological advances in robotics and miniaturization
(similar trends of course are observed in nearly any area of
research and technology development). We can now generate
very large volumes of data for a specific project, typically
for 104–106 diverse molecules. Data generation is resource
intensive, and data always contain experimental error. Outside
of the pharmaceutical industry, the availability of large volumes
of published, or otherwise public domain data in databases like
ChEMBL,40 PubChem,41 or ZINC42 has transformed the field.
2. Validation methods. A common method of validating a
QSAR model is by use of an external test set. Part of the data is
held aside, and the remainder used to train the model.
The model is used to predict the test set endpoints and a
metric for the accuracy of prediction is then calculated. A better
ways to simulate the natural evolution of a typical drug dis-
covery project is to use a time-split test set,43 i.e., assigning
compounds tested in later phases of the project to the test set.
It can be demonstrated that time-split gives a good estimate of
the R2 for true prospective prediction relative to random test
set selection (a standard method that can overestimate predic-
tion accuracy) and leave-class-out validation (which is too
pessimistic).43 Users of the ChEMBL database sometimes use
the date of publication as a surrogate time-split threshold.
Validation of QSAR models for properties of chemical mixtures
is more complicated. In that regard, the points out44 approach
is not different from traditional QSAR, but should be used only
for predicting the same mixtures with new composition. The
compounds out44 approach is suitable for predicting new
mixtures of compounds from the modeling set; the mixtures
out45 approach is for mixtures of one compound from the
modeling set and one new compound; and the everything
out46 approach (the most rigorous) is for mixtures of completely
new compounds.
3. Multitask modeling. In classical QSAR only one predicted
activity is modelled at a time. However, in drug development,
multiple activities, both on- and off-target, are needed for
prioritizing compounds. The set of techniques for prioritizing
compounds based on more than one predicted activity simulta-
neously is called multi-parameter optimization,47 or multi-task
modeling. In general, this objective can be achieved by an
ensemble of single task models, or by a single model that can
predict more than one activity simultaneously using either non-
neural net or neural net-based techniques, including deep
learning that has become popular in recent years. The multiple
activities could involve related targets in one species, the same
target in different species, the same target under different
experimental conditions, or be completely unrelated. Multitask
modeling is expected to be useful when data are sparse, i.e. not
all molecules are tested on all targets, and the hope is that
information will ‘‘leak’’ or ‘‘read across’’ different targets and
reinforce structure–activity trends. Several methods have been
proposed for multitask QSAR modeling including perturbation
theory + machine learning (PTML),48 inductive learning and
multi-objective optimization49 as applied in proteochemo-
metrics modeling.50 The most common way of handling multi-
task modeling currently is with deep neural nets, especially
convolutional neural nets. This will be discussed in more
detail in the section on ML methods. Multi-task optimization
represents an active area of development in QSAR modeling.
However, it is still unclear whether these techniques provide a
significant improvement in external predictive accuracy com-
pared to an ensemble of single task models developed for the
same end points. For example, an ensemble of individual
models developed with XGBoost (gradient boosting decision
trees) method exhibited the best performance in a recent 2019
IDG-DREAM Drug-Kinase Binding Prediction Challenge.51
As many compounds do have multiple biological activities,
there is an obvious need to continue both methodological
and application studies on multitask modeling in QSAR and
other areas of statistical data analysis.
4. Applicability domain (AD). An applicability domain52
defines the space of molecular features on which the model
has been trained and to which it should be applied; the AD
provides a means for estimating the reliability of property
predictions for new molecules from a QSAR model. It allows
flagging of less reliable predictions and helps identify addi-
tional molecules that might be required to expand the model
AD into more productive chemical spaces. Interestingly, AD is
one area where QSAR is ahead of the general field of ML,
although there is not yet a consensus on the best approach to
this issue.52
5. Modelability. Whether a statistically significant model can
be built from a given dataset depends on a number of
issues.53,54 If the size of the experimental error in the measured
dependent variable approaches the magnitude of the variation
across multiple molecules in the dataset, it becomes increasingly
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hard to generate meaningful models. The signal to noise ratio in
the data set is too low. Assuming this is not an issue, and
considering activity and descriptors together, the relatively new
concept of modelability55 proposes that predictivity of QSAR
models is then limited by activity cliffs. As discussed above,
activity cliffs exist when very similar compounds have very differ-
ent activities, making the target property of compounds near the
activity cliffs hard to predict.23 This difficulty is not easily over-
come by changing either the QSAR method or the descriptors
used. One exception is that using stereochemically-aware descrip-
tors can reduce activity cliffs where different stereoisomers exhibit
very different activities. Metrics that measure the prevalence of
activity cliffs in a dataset are good predictors of themodelability of
that dataset.55 Clearly, these metrics cannot distinguish activity
cliffs that are intrinsic to the SAR response surface from those that
are artifacts due to large experimental uncertainties in the mea-
sured activities.
6. Interpretability. Early classical QSAR methods were rela-
tively simple and tended to deal with molecules that were close
analogs. Comparative molecular field analysis (CoMFA)56 was
extremely successful because of its visual appeal – it was clear
where and how to modify a molecule to increase its activity.
Later, projection of atom/fragment model contributions onto
exemplar molecules has been suggested.57 However, as model-
ing methods have become more sophisticated, descriptors
more arcane, and datasets more diverse, the accuracy and
breadth of predictions have increased at the expense of inter-
pretability (understanding the molecular basis for good or bad
activity of molecules that guides design of improved examples).
Methods that ‘‘see’’ into the black box of QSAR models inde-
pendent of the descriptors and QSAR methods used are dis-
cussed in a recent review.58 An important process in QSAR
modeling is selecting the most relevant subset of descriptors
for a much larger pool in a context dependent way (sparse
feature selection,59 which we also touch on in the section on
biomaterials and regenerative medicine below). This improves
the ability of models to generalize well and can make inter-
pretation easier because fewer descriptors are used in the
model. Subsequently, models are usually interpreted in two
ways. The first is to determine which descriptors are the most
important for driving improved properties of molecules. This is
called ‘‘descriptor importance’’ for QSAR58 or ‘‘feature impor-
tance’’ for ML in general. The second, applicable to models
trained on substructure-type descriptors, is to project the most
important features from the model onto exemplar molecules to
highlight structural features associated with more favorable
activity.60 A molecule with atoms colored according to their
contribution represents a molecular ‘‘heat map.’’ Another
important, descriptor- and model-independent method for
interpreting features is to apply small perturbations to the
input descriptors one at a time, while holding the other
constant, and observing the effect on the modeled property
(sensitivity analysis, effectively generating partial derivatives
of the response with respect to the descriptors).61 These
approaches to interpretation have limitations as well.62 It is
important to recall that no statistical method can distinguish
correlation from causation, and interpretations cannot always
be related to a mechanism. A practical approach towards
mechanistic interpretability, lateral validation,63 is to observe
trends across related phenomena: When the choice of variables,
the sign and size of their coefficients are similar across multiple
QSARs, this may help mechanistic understanding and perhaps
causation.
7. ML methods. There are many standard methods of ML in
QSAR.64 The current wave of enthusiasm is for deep neural nets
(DNN) as the ML method. Because of their relative recency and
popularity across many disciplines, comparison of DNN with
other popular ML approaches is presented below.
DNNmethods are attractingly widespread application across
many disciplines.65 Single hidden layer neural nets were a
popular ML method for developing QSAR models in the
1990’s However, neural nets have undergone a renaissance
in the past decade. Algorithmic improvements, advances in
hardware, use of GPUs, etc., have made DNNs practical and
computationally tractable. In AI applications, such as image
classification or speech recognition, DNNs have been shown to
be superior to any techniques that came before. DNNs began
to be applied to QSAR66 after the Merck Molecular Activity
Challenge in 2012.67 In less than a decade we have seen an
enormous growth in publications using diverse DNN architec-
tures for modelling chemically-related properties.
To put DNNs into context for QSAR, there are many other ML
methods used in QSAR modeling including k-nearest neighbors
(kNN),68 partial least squares (PLS),69 support vector machines
(SVM),70 relevance vector machines, (RVM),71 random forest
(RF),72 Gaussian processes (GP),73 and boosting.74 In the pharma-
ceutical industry (in fact, in any discipline), ML and DNNmethods
can be compared to older methods by the following:
1. Prediction accuracy
2. Number of sensitive and tunable hyper-parameters
3. Need for descriptor selection
4. Length of training time
5. Length of prediction time (including uploading the model
into memory)
6. Domain of applicability (determined mainly by descrip-
tors and training set characteristics)
7. Interpretability of models
RF has been a popular choice for QSAR modeling for many
years as it can make very good predictions, has few adjustable
parameters, and can be parallelized. Moreover, the degree of
agreement of predictions of different agreement of RF trees75
can help define the AD. Boosting is also very useful because it is
often one of the most accurate and fastest methods, especially
with the latest implementation of extreme (XGBoost76) and
light gradient boosting machine.77
The case for DNNs as a ML method would be made based on
its superior predictivity. Comparison of DNNs to other ML
methods like RF and XGBoost on standard industrial QSAR
datasets shows a statistically significant improvement in
prospective predictions as shown in studies conducted by
some of the authors of this paper, and similar conclusions
have been published elsewhere.78 However, in absolute terms,
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the improvement is less than notable. When trained on the
same data sets and descriptors, DNN predictions are not
different to those of other methods.79 Thus, the squared
correlation coefficient (R2) of models generated with DNN was
only 0.04 higher (on average) than those built with RF as shown
in Fig. 4. This is consistent with the universal approximation
theorem discussed below.
Deep neural nets also have undesirable characteristics such
as requiring more tuning of training parameters for a given
training set, being computationally more demanding, taking
longer to predict, and being harder to interpret.
Why are DNN models not making substantially better
predictions than the other ML methods? A fundamental reason
is the universal approximation theorem that states that single
layer neural networks (and ML methods mathematically
similar) are sufficient to model any nonlinear function given
sufficient data.80 Another reason may be that any pharmaceu-
tical data set inevitably has experimental errors that will
compromise very accurate model generation. Training and test
sets are also not necessarily similar, and the new field of
modelability suggests that all QSAR methods are limited by
the presence and size of activity cliffs.81 For these reasons, more
sophisticated and flexible methods will not necessary provide
better predictions.
It is important to remember that in the pharmaceutical
industry, unlike other areas where ML is applied, the data
required to build models is limited, expensive, and resource-
intensive.64 Getting marginally better predictions is not useful
when the bottleneck is data paucity. However, DNNs methods do
have very important advantages over most other ML methods:
1. They can straightforwardly model more than one activity
at a time (multi-task models);82 the same is true for single layer
NNs with multiple output nodes83 but not so for other ML
methods. It has been claimed that on the average this produces
better predictions than models of the individual activities.
In practice, this effect can be quite modest, exhibiting both
improvements and degradations in prediction for individual
activities. It has been shown that improvement relies on the
training set for the activities sharing similar compounds and
features, and there being significant correlations between the
activities.84
2. Their ability to automatically generate novel chemical
features (using, e.g., graph convolutional neural networks,
CNNs) is particularly important.85 This mimics how images
are processed on the fly (with atoms replacing pixels), as
opposed to the use of pre-generated chemical descriptors.
The premise is that by generating richer molecular features,
more predictive models will result. In some cases, CNN has
provided more accurate predictions than descriptor based
DNNs.85 For example, CNN is better at predicting quantum
chemical energies.86
3. They provide the possibility of inverting the QSAR model
(inverse QSAR), i.e. designing molecules directly from the
model (so called generative models).87 This is in contrast to
the current QSAR practice that only goes in the direction of
property prediction from structures, not from properties to
predicted structures. Candidate molecules must be generated
by screening large virtual libraries or by assembling or swap-
ping chemical fragments and predicting their properties by a
QSAR model.
To summarize, it is still unclear from the ML literature
whether DNNs are distinctly better at QSAR tasks than standard
methods, because in most cases an exhaustive comparison has
not been made. We would recommend that the method in
question must always be compared to a good off-the-shelf ML
method (such as RF or boosting) in the context of QSAR best
practices.18 We would also recommend that a fairly large
number of datasets (410) should be examined in any given
study. This removes the temptation to cherry-pick the results
that make the method under study look better.
Another issue is the tests for DNN performance represent a
low bar for success, meaning that predictivity appears better
than it is in practice (an issue for the entire QSAR area).
Random-split validation (which is still a literature standard)
makes predictions that appear to be good because the test and
training sets cover about the same chemical space, a difficult
constraint as predictions outside of the model AD are likely to
be poor. We recommend a time-split validation where possible,
checking that the test set compounds are not too far from the
model domain. Another practice in ML is to tune hyper-para-
meters using a validation set, where both the validation and
test sets have been chosen from the same pool of compounds.
In effect, this lets information about the test set to leak into the
training set of the model, which makes predictions overly
optimistic, and thus this practice should be avoided. The
enthusiasm for DNN methods has sometimes encouraged bad
practices, such as not comparing results to simpler methods
(Occam’s Razor) and publishing non-reproducible models, as
has been reported in other areas of machine learning.88
In our opinion the current enthusiasm for DNNs in QSAR is
not yet justified by its slightly increased predictive performance,
given that the methods are compute-intensive and the models
very hard to interpret. However, it should not be overlooked that
Fig. 4 Comparison of the Pearson R2 values for models generated using
DNN (blue) or XGBoost (red and green) and random forest methods.
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their main advantage in in the generation of novel and useful
features from relatively simple representations of molecules (or
materials) and the potential for inverse QSAR. The development of
new methods for DNN model interpretation such as layer-wise
relevance propagation will also increase their advantage over
traditional QSAR methods.89 Clearly, given how fast the field is
developing, it is hard to know whether DNNs will overcome
current disadvantages, although the inexorable increase in com-
putational resources available will ease some of them. On the
other hand, the enthusiasm for DL methods is driving a renais-
sance in the use of ML in chemistry,90 creating more opportunities.
As computational chemists, we should be actively researching
other fields like data science andmathematics for advances in ML
methodology. Historically, we have acquired new ML methods
through serendipity, because we tend to read only the chemical
literature. For example, the author of this section started applying
RF to QSAR in 2003 because of a chance conversation with
statisticians. We became aware of DNNs only after the Kaggle
contest in 2012 and of XGBoost in 2016 because of a suggestion
from a person in the IT department. However, the criteria we
proposed for how DNN and ML methods should be compared,
and concerns and suggestions on how best to generate dataset
splits to enable robust assessment of model predictivity, have
originated from our experience in QSAR modeling. These learn-
ings will undoubtedly be valuable for other areas of statistical data
modeling. The above examples suggest that exchange of best
practices and methodologies between QSAR modeling and other
fields will bring advances in both. Better definitions of important
general concepts such as applicability domain or model interpret-
ability are applicable to other diverse disciplines.
QSAR in chemical safety assessment
QSAR approaches have been used extensively to model impor-
tant drug properties such as ADMET. Minimizing toxicity and
optimizing pharmacokinetics is critical for designing new and
safe medicines; incorrect estimation of these parameters can
result in undesired side effects and affect in vivo efficacy,
leading ultimately to a failure of a drug candidate. It should
be noted that almost any chemical is toxic at a sufficiently high
dose, so an important characteristic of any drug is its thera-
peutic index, the ratio of the effective dose causing the desired
therapeutic effect in 50% of research subjects (ED50) to the drug
dose causing adverse effect(s) in 50% of the subjects (TD50).
Thus, it should not be surprising that even extremely toxic
compounds such as snake venom toxins are useful, at proper
concentrations, as diagnostic probes,91 drug leads, or even as
therapeutic agents.92 Chemical toxicity is also very important
for the assessment of the occupational health and environ-
mental safety. Because toxicity is a complex multifactorial
phenomenon caused by chemical effects on biological systems,
it is important to understand underlying toxicity mechanisms
to build mechanistically meaningful prediction models. There
is a clear need to develop standardized protocols when
conducting toxicity-related predictions, and the information
needed for protocols to support in silico predictions for major
toxicological endpoints of concern (e.g., carcinogenicity, acute,
genetic, reproductive or developmental toxicity) across several
industries and regulatory bodies has been discussed elsewhere.93
Below, we review several key concepts that relate to issues in
chemical toxicity prediction.
Adverse outcome pathways (AOP)
AOP is one of the key concepts of toxicity assessment.
It assumes that toxicity is initiated by a molecular initiating
event (MIE), which leads to an adverse outcome (AO).94 A single
AOP describes a sequence of linked events starting from MIE,
going through a cascade of linked key events (KEs), and ending
at an adverse health or ecotoxicological effect. The adverse
outcome pathway knowledge base is currently under active
development for both health and eco-toxicology studies.95 With
knowledge of AOPs, QSAR modeling can be used to identify the
potential of chemical compounds to cause a MIE and/or to lead
to an adverse outcome.
Importantly, metabolites can also cause toxicity even when
the precursor has low toxicity. Therefore, incorporation of
information about metabolic activation can improve toxicity
QSAR models.96 AOP facilitates mechanistic interpretation of
models, provides a better understanding of toxicity, and allows
the development of new in vitro tests.97 Currently, the develop-
ment and validation of such tests is an emerging topic in
predictive toxicology.
In vitro toxicity and Tox21
Tox2198 is a high-throughput toxicity evaluation initiative
supported by several government agencies including US
Environmental Protection Agency (EPA), National Institutes
of Health (NIH), and Food and Drug Administration (FDA).
Similar initiative exists in Europe under the REACH
(Registration, Evaluation, Authorization, and Restriction of
Chemicals) legislation. REACH encourages the use of so-called
alternative approaches or surrogate end points to reduce
animal testing. Naturally, QSAR modeling represents one of
the best alternative approaches for risk assessment because it
can be used both to predict in vitro activities of compounds and
to combine these in vitro results with computed molecular
descriptors to improve the accuracy of models in predicting
in vivo effects. The requirements for using QSAR models for
regulatory purposes have been reviewed elsewhere.99
Tox21 data have been used actively by the cheminformatics
community to test both the prediction accuracy of QSAR
models and to understand current limitations of the field.
The Tox21 data challenge aimed to assess the ability of QSAR
models to predict important in vitro endpoints related to
chemical toxicity.100 Participants predicted the outcomes of
12 cellular stress assays.100 The winning team (as determined
by the AUC metric) used a DNN to build multi-task models for
these outcomes.101 Model built with an associative neural
network102 had similar prediction performance. The results of
the Tox21 challenge indicated that recent progress in neural
networks have accelerated development of robust and predictive
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QSAR models for in vitro toxicity. The development of new types
of DNN90 has opened up new applications, allowing simpler
molecular representations, such as SMILES strings or chemical
graphs to be used to generate useful toxicity (and other property)
models. However, these methods have generally lower predic-
tion accuracy than ML approaches using traditional QSAR
descriptors.103 DNN methods also require substantially larger
datasets to fully capitalize on their advantages,90 a problem that
is rapidly abating due to explosive growth in chemical data that
is driven by automation.
Tox21 data also gave rise to a number of notable compre-
hensive studies, such as collaborative estrogen receptor (ER)
activity prediction project (CERAPP)104 and collaborative
modeling project for androgen receptor (AR) activity (CoMPARA),
involving 17 and 25 international teams respectively. The resulting
consensus QSAR models leveraged knowledge from the groups
and were used to predict ER and AR potentials of 32464 new
chemicals.
It should be emphasized that development of new experi-
mental techniques such as deep-sequencing RNA-Seq,105 pro-
vides new types of data for in vitro assessment of toxicities that
can also be used for QSAR modeling.106
In vivo toxicity
Given that adverse reactions could be caused by a multitude of
factors, prediction of in vivo toxicity is arguably the most
difficult task in QSAR modeling. The cost and ethical issues
associated with direct in vivo toxicity assessment means that
data to train models is scarce, so models are quite limited. This
is clearly illustrated by the results of ToxCast lowest effect level
prediction challenge.107 The highest prediction accuracy with
the lowest RMSE of 1.08 log units was achieved using a consensus
prediction of associative neural network102 models developed with
several sets of descriptors.107 Although the organizers of the
challenge have offered a set of in vitro measurements performed
within the ToxCast project, the top-ranked model was exclusively
based on the calculated descriptors and was not improved by
adding in vitro data as descriptors.107 The failure of this107 and
QSARWorld bioavailability challenge indicates critical importance
of data curation.16 Availability of more in vivo data, application of
more complex methods such as those based on physiologically-
based pharmacokinetic (PBPK)models,108 better data curation16 as
well as new descriptors, which account for pharmacokinetics,
should improve the model accuracy. Since in vitro assays in
ToxCast were not predictive of such complex endpoint,109 other
methods, such as those based on systems chemical biology,110 or
more complex assays such as RNA-Seq used in combination with
gene interaction networks, may be more successful.111 Indeed, it
was reported that combination of in vitro and in silico predictions
contributed better models for a number of in vivo endpoints.112
Multitask modeling: an approach that should not be
overlooked
Multitask modeling leverages information from multiple corre-
lated properties and may provide models with higher predictive
power than individual QSAR endpoint models. This is attributed
to read-across and the existence of mutual information in the
more complex multiple end point data sets. A recent study showed
that multi-task modeling consistently improved the accuracy of
models for prediction of 29 in vivo endpoints using 87K chemical
structures collected from the registry of toxic effects of chemical
substances (RTECS) database.113 Importantly, authors suggested
that the significantly improved toxicity predictions of multitask
models should reduce the need for animal testing, prompting
revisions to the current regulatory guidelines.
Structural alerts and QSAR
Identification of molecular features associated with toxicity
(structural alerts) represents a tool because it can help reduce
unwanted side-effects of compounds by removal of offending
moieties. However, toxicity alerts generally have lower predic-
tion accuracies compared to QSAR models.114 It has also been
suggested that a combination of alerts or any other structural
rules115 and QSAR models may provide improved guidance for
rationally designing new compounds with reduced toxicity.114
These combined approaches were further developed by the
chemistry-wide association study (CWAS) that predicted
Ames mutagenicity and an adverse drug reaction known as
Stevens–Johnson syndrome.116 The identification of important
chemical fragments and analysis of their co-occurrences also
allows mechanistic interpretations of QSAR models without
compromising their accuracy.
In summary, this section provides a brief review of a special
area of QSAR modeling that deals with chemical safety.
However, even in this highly specialized application there are
components that can be generalized to other applications.
Multi-objective modelling and optimization is one such
approach that will be increasingly used in other disciplines.
The ability to interpret complex statistical models for any target
effect is important in many fields, especially when building
models of large data sets using deep neural networks.117 These
examples reiterate the conceptual overlap between many
elements of QSAR modeling and challenges faced by other
disciplines.
Multi-target profiling and
polypharmacology
Since the beginning of the 20-th century, the concept of
‘‘a magic bullet’’ has served as the basis for drug discovery and
development.118 According to this concept, a drug should be
developed with the highest selectivity toward the intended
target for a particular disease. Thus, classical QSAR/QSPR
studies have been performed with training sets of compounds
active in a single biological assay; frequently, all compounds
also belong to the same chemical series.1
The advent of high-throughput screening technologies and
proliferation of diverse assays have enabled screening of a
larger number of molecules in more diverse assays. Conse-
quently, it is now generally accepted that the majority of
pharmaceutical agents interact with several, sometimes many,
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biological targets. This often generates beneficial therapeutic
activities,118 due to additive or synergistic pharmacological
effects.119 On the negative side, drugs can also interact with
undesired molecular targets to causing adverse or toxic effects
that often block further development. Clearly, there is a strong
need to understand both the beneficial and adverse polyphar-
macology of ligands.120
Discovery of molecules with beneficial polypharmacology
could be achieved by the experimental evaluation of millions
of drug-like compounds against thousands of targets.121
Currently, this is an unrealistic task, particularly taking into
account the variability of results obtained for the same ligand–
target interaction in different assays, and relatively low hit rates
of experimental screens.122 Thus, in silico prediction of bio-
logical activity profiles by (Q)SAR models is a viable alternative
to these intractable experimental screens. Importantly, virtual
screening approaches may be applied to millions of virtual
molecules designed in silico.123 Such virtual screening greatly
reduces both the number of molecules needed to be synthe-
sized and tested, allowing pre-selection of likely hits and
reduced time and cost in synthetic chemistry programs.122
Multi-target profiling of compounds has led to the concept
of the biological activity spectrum,124 defined as the set of
different biological activities resulting from the compound
interaction with different biological systems. It therefore repre-
sents an ‘‘intrinsic’’ property of the compound that depends
only on its chemical structure.
Several approaches for multi-target modeling have been
proposed. One of the earliest developments in this area was
the computer program PASS (prediction of activity spectra for
substances) reported by Filimonov et al. almost 30 years ago.125
PASS employs a uniform set of multilevel neighborhoods of
atoms (MNA) molecular descriptors and a Naı¨ve Bayes classifier
to model structure–activity relationships across a wide variety
of biological assays. This approach allows the prediction of a
wide range of biological activities at molecular, cellular, organ/
tissue and organism levels. It can predict pharmacotherapeutic
effects, mechanisms of action, specific toxicities, terms related
to drug metabolism, gene expression, etc. The current version
of PASS predicts several thousand biological activities based on
the analysis of structure–activity relationships in the training
set of over one million biologically active compounds.126 More
recently, Gonzalez-Diaz et al.127 developed the perturbation
theory machine learning (PTML) methods that search for QSAR
models capable of simultaneous prediction of many target
properties under several experimental conditions.
Substantial amounts of relevant chemogenomics data have
recently became available from PubChem, ChEMBL, and other
public sources. This has catalyzed a resurgence of freely
available Web-accessible tools for bioactivity predictions and
continuing development of new QSAR tools and methods.
In contrast to PASS online,124 which is an open access
Web-service for predicting biological activity spectra, most
other tools focus on predicting putative molecular targets for
compounds of interest. They use training sets extracted from
publicly available data sources, different types of chemical
descriptors,128 and prediction methods based on implementa-
tions of different chemical similarity searches.129 Despite some
disadvantages,130 such approaches remain an accessible way of
predicting compound activity against novel pharmacological
targets lacking sufficient training data for building accurate
QSAR models.131 If the number of known ligands is sufficient
for model building, some web portals provide an option to
predict compound activities using conventional QSAR.
It is challenging to compare the performance of multi-target
profiling tools. In contrast to single target models, there is a
paucity of evaluation sets of compounds reproducibly tested for
several types of biological activity. Thus, only a few comparative
studies have been reported to date. For example, using data on
affinity of drug-like compounds against several GPCRs, the
performance of a collection of multiple target-specific k-nearest
neighbors (kNN) QSAR models, PASS124 and similarity ensemble
approach (SEA)132 was compared.133 The best results were
obtained with the kNN method, while PASS demonstrated a
moderate predictive accuracy and SEA shown the lowest prediction
power across multiple targets.
Recently, a large evaluation set including half a million
compounds tested across more than 1000 assays was con-
structed from ChEMBL data.134 The performance of several
ML methods was evaluated, and deep feed-forward neural
networks (FNN) generated the best results, while SEA showed
the lowest predictivity. It is noteworthy that all ML methods
showed relatively small differences in predictive accuracy and
the advantage of the DNN was not readily apparent. This
conclusion appears reasonable given that the principal purpose
of DNN development was image feature recognition, i.e., simi-
larity assessment but not prediction. Similar observations of
the lack of advantage offered by DNN in cheminformatics
compared to conventional ML was also made in the preceding
section on modeling chemical toxicity.
As also noted in the preceding section of this paper, multi-
task learning represents one of the major directions of QSAR
development. A natural extension of multitarget QSAR is the
analysis of ligand–target interactions in combined chemical–
biological space, so called chemogenomics.135 Several hundred
papers have been published on new methods and applications
for chemogenomics (some discussed in greater detail in
the following sections). For example, Gupta-Ostermann and
Bajorath reported the structure–activity relationship (SAR)
matrix method, which predicts activities and allows navigation
in multi-target activity spaces.136 March-Vila and co-workers
have summarized the promise of chemogenomics applications
for drug repurposing.137
A recently proposed proteochemometrics (PCM) approach
employs relevant information from target sequences and com-
bines it with ligand descriptors to develop models predicting
ligand–receptor (class of) binding affinity. This approach is
more useful than ligand-based modeling in cases when the
same ligands show differential binding affinity to diverse
targets. Several interesting applications of the PCM approach
have been reported. For instance, this approach was used to
predict ligand interactions with wild-type and mutated
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a-adrenoceptors where it has demonstrated superior predic-
tivity in comparison with conventional QSAR methods.138
In other study, Lapins et al.139 applied PCM method to predict
inhibition of five major drug metabolizing isoforms of cyto-
chrome P450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and
CYP3A4) by drug-like compounds. A recent study, has also
demonstrated significant advantages of PCM approach and
inductive transfer of knowledge between the targets over tradi-
tional methods.140
Careful review of the published results of PCM modeling
leads to the conclusion that it may provide good estimates of
ligand–target affinity in a single model by combining data from
multiple assays (Fig. 5). However, to achieve this goal, substan-
tial efforts must be applied to standardization141 and curation16
of such data.
To conclude this section, we note that training sets used to
develop conventional QSAR models do not exceed millions of
entries, while the estimated size of drug-like chemical space is
up to 1060 molecules.142 We expect that with the growth of
chemogenomic data and expansion of the studied chemical
space, the multi-target QSAR modeling will become more
common than single-target QSAR studies and that multi-target
QSAR will lead to the discovery of novel medicines with
much improved safety and potency profiles. Another important
projection is that further development of multi-objective
optimization methods will not only expand the field of poly-
pharmacological QSAR but will also find use in many other
predictive disciplines where multiple objectives need to be
optimized.
QSAR-like approaches in genomics
Genomic and HTS (high throughput screening) data have rarely
been subjected to QSAR analyses. Indeed, typical workflows
require hit confirmation and validation prior to (Q)SAR
modeling, and cheminformatics-based prioritization schemes
based on individual compounds as well as scaffolds have been
proposed.143 One of the major obstacles to date remains
the absence of the gene-based descriptors suitable for ML.
However, high throughput driven biomedical knowledge accu-
mulation has created an urgent need for Big Data analytics in
genomics and HTS to help with the evaluation, interpretation,
and integration of data, and with development of respective
models.
From a life sciences perspective, the use of DNN can gene-
rate novel applications and even entirely new meaning to the
field of chemical genomics by directly linking the structure of
the molecule to its effect on genes, and by embedding these
linkages in models that predict gene-mediated effects of che-
micals in vivo. Such models require the combination of input
features that characterize both small molecules (i.e., chemical
descriptors) and genes (e.g., gene expression profiles) or HTS
results for training. Only a few studies have been published in
this area so far. For instance, it was demonstrated that gene
ontology (GO) terms144 and HTS results can be translated into
input features for cheminformatics models.145 In another such
study, Sedykh et al.146 described and implemented a workflow
for using HTS data in combination with molecular descriptors
to predict in vivo toxicity. In a related work,147 in vivo rat oral
toxicity was predicted by combining endpoints of 499 HTS
assays (biological variables) with 548 circular Morgan descrip-
tors (chemical variables). Notably, when used separately, bio-
logical descriptors resulted in a model with lower statistical
significance than the model based on chemical descriptors.
Another example of ‘hybrid’ QSAR modelling shows how
QSAR descriptors and GO terms can be combined within
a unified QSAR model capable of predicting the effect of a
given molecule on a particular gene.148 Specifically, levels of
expression of 1000 ‘hallmark genes’ in six cell lines were
predicted by DNN-classifiers, where for every molecule–gene
pair in the training set, circular Morgan fingerprint values
(molecular descriptors) were combined with GO terms used
as gene descriptors. The resulting DNN models built with back-
propagated feed-forward fully connected multi-layer perceptron
(MLP) with four layers yielded good prediction accuracies
(cross-validated area under the curve (AUC) values were in
the 0.80–0.83 range). These results suggested that ‘hybrid’
DNN models can rather accurately associate genes and small
molecules to up- or down-regulation.
Seventeen different protein- and gene-centric data sources
totaling over 262.3 million data points were integrated into
knowledge graph representation with typed nodes and edges,
which enable the conversion of the gene-based information
into descriptors suitable for ML via network-based analytical
algorithms.149 Specifically, a set of 103 genes having autophagy
(ATG) associated annotations from GO terms, UniProt150 and
KEGG,151 were used to derive ML models using the metapath
approach combined with the XGBoost algorithm.152 These
binary ML models were trained to distinguish ATG genes from
non-autophagy genes (cross-validated AUC values were in the
0.95–0.99 range). Of the top 251 predicted novel genes, 23%
Fig. 5 Proteochemometrics approach enables accurate affinity estimates
for novel ligand–target pairs.
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were associated with ATG based on literature queries, whereas
193 were not.
These case studies offer an important example of QSAR
modeling evolving towards the use of more complex datasets.
Synergistic use of features representing both chemical and
biological properties, including gene expression profiles, GO
terms and KEGG pathway associations combined with ML
methods, are generating promising results. This increase in
complexity is typical for many areas of research where DNN and
gradient boosting methods are finding growing applicability.
The improvements in model accuracy achieved by ML appro-
aches may have been modest so far, but the prediction power of
these models may increase in near future due to cross-fertiliza-
tion of ideas on using ML for data modeling both in chemical
datasets as well as in many other areas of science and technology.
It is tempting to speculate that DNN technology can directly screen
virtual chemical libraries for compounds with bespoke, useful
modulation of target genes and gene networks.
As the sources of data and sizes of datasets describing
the biological properties of small molecules grow, there is also
a concomitant demand for knowledge management (KM) systems,
that integrate heterogeneous data into unified, predictive models
and translate data into information.153 For example this might
allow merging of experimental bioactivity data for small
numbers of molecules, 3D information from experimentally
resolved structures of protein targets for these molecules, statis-
tics of respective drug adverse event reports, and high-volume
(often lower quality) data such as genome-wide association
studies (GWAS) or HTS. Such large scale datasets are already
assembled into knowledge graph systems, for example
Pharos,154 which supports in-depth exploration of the druggable
genome.155 Modelling such data viaML, sparse feature selection,
and other advanced algorithmic approaches may lead to a better
understanding of the associations between chemical structures
and proteins and genes in an unbiased, objective manner. They
could further help identify novel gene–phenotype associations,
either for diseases or for physiological phenomena such as
autophagy.
QSAR in synthetic organic chemistry
The application of QSAR modeling to challenges faced by
synthetic organic chemists is a recent and exciting development
in predictive computational chemistry.156 Rapid growth in
robotic platforms for drug and materials design has stimulated
the development of reliable cheminformatics tools to assist
with efficient synthesis of target molecules. These tools esti-
mate synthetic accessibility of a target molecule and suggest
feasible synthetic routes (Fig. 6). Two of the most widely used
synthesis planning strategies are forward synthesis (starting
from specified building blocks) and retrosynthesis (starting
from a specified target molecule). Synthetic routes usually
contain multiple reaction steps for which major products
and, ideally, kinetic parameters must be predicted by models.
Once a given elementary reaction is selected, reaction conditions
(solvent, catalyst, temperature, etc.) leading to a reasonable yield
should be suggested by the algorithm. The above considerations
can be met by a wide range of cheminformatics tools, some of
which are currently used in a computer-aided synthesis design.157
In this section we briefly describe reaction data availability,
visualization, and analysis, and summarize recent studies
focused on different parts of the modeling workflow described
in Fig. 6.
Reaction data availability
Newmodeling tools need access to large volumes of experimental
reaction data stored in public and proprietary databases. In most
of the recent studies, the Reaxys database (440 M reactions
including 12.5 M one-step reactions),158 the USP database
extracted from US patents (41.2 M reactions),159 and the QSRR
database (B10000 reactions) have been employed. Generally,
reaction data from public databases is of mixed quality. Many of
the reactions are stoichiometrically unbalanced, some important
data on reaction conditions are missing, and different names are
used for the same catalysts or solvents.160 However, no standards
for reaction data curation have been reported so far. Ignoring the
data curation step of the modeling workflow will significantly
affect the quality of the training data and models derived from
them.16
Reaction encoding
Chemical reactions constitute a very complex modeling pro-
blem in cheminformatics. A reaction equation involves several
different types of molecular graphs (for reactants and products)
and its yield depends on numerous experimental conditions.
Depending on ML method used, chemical structures can be
encoded by SMILES (e.g., in sequence-to-sequence models161)
Fig. 6 Main tasks of computer-aided synthesis design. As soon as a
synthesis planning for a target molecule is established, efficiency of each
one-step reaction and related optimal reaction conditions could be
assessed.
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or by descriptor vectors, or a combined fingerprint (resulting
from concatenation of descriptors of reactants and products162),
or subtraction of descriptors of reactants from descriptors
of products.163 The latter may require balanced reaction
equations that, in turn, need a specific data curation step.163
Alternatively, a chemical reaction (balanced or unbalanced) can
be encoded by the condensed graph of reaction (CGR). This
merges reactant and product structures into a single molecular
graph employing both conventional chemical (single, double,
etc.) and ‘‘dynamic’’ bonds characterizing observed transforma-
tions (e.g., single and double bond breaks, single-to-double
bond conversion, etc.).164 CGR can be consider a pseudomole-
cule to which any cheminformatics approaches can be applied.
In particularly, fragment descriptors or fingerprints can easily
be generated for CGR.165 Solvent can be encoded by a set of
physico-chemical parameters which can be concatenated with
the structural descriptors.
Visualization and analysis of reaction space
Both graph-based and vector-based approaches have been used
to visualize the chemical space of reactions. In graph-based
approaches, chemical reactions and individual molecules
(reactants and products) are represented as nodes of a large
bipartite graph166 used to optimize synthetic pathways. In the
vector-based case, a chemical reaction is defined as a vector in
multidimensional space defined by descriptors. Dimensionality
reduction is required to generate a two-dimensional map
describing the data distribution. This approach was pioneered
by Gasteiger et al.167,168 who generated self-organized maps
(SOM) that clustered different classes of reactions effectively.
Generative topographic mapping (GTM) approaches have
recently been used to visualize large sets of SN2, cycloaddition,
and tautomerization reactions. Unlike SOM and many other
dimensionality reduction methods, GTM can be used to predict
properties of new reactions projected on the map. As a pre-
dictive tool, GTM performs similarly to conventional ML meth-
ods like SVM.
Planning organic synthesis using prediction of reaction
products and retrosynthetic analysis
The general aim of synthesis planning is to identify a series of
feasible reaction steps leading to a target compound from
available starting materials. Retrosynthetic methodology,
invented by Corey,169 is a real challenge because the search
for precursors of a product generates a combinatorial explosion
of possible reaction routes. Cheminformatics tools can help
select the most feasible series of single-step reactions. The
current trend in this field is to train DL models on large sets
of reactions to predict probabilities of different retrosynthetic
transformations. It was shown that using Monte Carlo tree
searches and symbolic AI methods, it is possible to identify
feasible reaction pathways.170
Prediction of reaction outcomes allows one to prioritize
retrosynthetic suggestions. A cheminformatics tool should predict
the products of a given set of reactants under given conditions.
Consideration of multistage chemical transformations and
competitive reactions will significantly complicate this problem.
Current trends in the modeling of reaction outcomes focus on
processing large reaction databases with DL models to predict the
probabilities of competitive chemical processes.171 The latter can
be used directly for reaction outcome predictions. The Reaction-
Predictor tool172 is of particular interest because it forecasts the
output of complex chemical reaction by combining mechanistic
considerations with ML. This approach enumerates possible
interactions and then ranks them using a pseudomolecular
orbital approach.
Two orthogonal methodologies, template-based and tem-
plate-free, can be applied to retrosynthesis and outcome pre-
diction. Template-based methods rely on user-established sets
of transformation rules, either suggested by expert-chemists or
extracted automatically from reaction databases, the feasibility
of which is assessed by the model. This concept is employed in
most retrosynthetic tools, including the popular CHEMATICA
program,173 which integrates more than 10 000 empirical trans-
formation rules.
Alternatively, in template-free approaches transformations
between the reactants and the products of chemical reactions
are deduced directly from their structures. This allows one to
automatically enlarge the list of transformation rules as soon as
new data are available. This methodology has become more
popular in recent years. For instance, Coley et al.174 suggested
using a graph-convolutional neural network and a global atten-
tion mechanism, followed by the application of rules to reac-
tion product predictions and retrosynthetic analysis. Another
template-free approach employs natural language processing
methods, namely ‘sequence-to-sequence’ models. These use
recurrent neural networks (RNN), commonly applied to transla-
tion of texts between languages. When applied to chemical
reactions, SMILES strings of reactants and products constitute
the language. This methodology was applied to model reaction
products and for retrosynthetic reaction route prediction,
which provided similar performance (ca. 37% for top-1) to
rule-based systems (35%).161 A use of an advanced transformer
architecture, which was initially used for English-to-German
translation, boosted the accuracy of predictions to about
43%.175 This result indicates that retrosynthesis predictions
can be significantly improved by algorithms originally developed
for very different purposes.
Forward synthesis planning
One of the most impressive approaches to forward synthesis
planning has been implemented in the DOGS program.176 This
algorithm applies 58 well-established chemical transformation
rules to a set of 25 144 readily available synthetic blocks from
the Sigma-Aldrich catalog. New molecules are grown in a
stepwise procedure, each step consisting of complete enumera-
tion of all possible solutions followed by selection of top
scoring intermediate products to subsequent growing steps.
The quality of designed products is assessed using pairwise
similarity to a target molecule. Thus, DOGS can usefully suggest
a synthetic plan not only for the target molecule but also for its
close analogs.
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Assessment of synthetic accessibility
Synthetic accessibility (or the opposite, synthetic complexity)
is a scoring metric used to prioritize virtual compounds for
synthesis. It is often used as an important filter for screening
virtual libraries and in de novo design studies. Among scores
developed so far54 the most popular is SA score.177 It is
calculated using contributions from fragment occurrences in
PubChem compounds and a complexity penalty based on the
number of chiral centers, rings, macrocyclic fragments, and the
total number of atoms. Recently, Coley et al.178 suggested
the synthetic complexity score (SCS) which relies on a neural
network trained on 22 million reaction pairs from the Reaxys
database.
Prediction of kinetic and thermodynamic characteristics
The logarithm of the reaction rate constant (log k) is a common
endpoint in QSAR modeling, first used more than 70 years
ago.179 Currently, quantitative structure–reactivity relationship
(QSRR) modeling is performed on large and diverse datasets
that account for solvent effects and temperature for many types
of chemical reactions using NN approaches.180 In these models,
descriptors computed for the reactants are concatenated with
solvent and temperature descriptors. This technology must
know the order of reactants in the reaction equation, making
the development of an automatized QSRR workflow proble-
matic. This problem can be solved using condensed graphs
of reaction (CGRs) that combine the reactant and product
information. Fragment descriptors generated for CGRs were
concatenated with solvent and temperature descriptors and
used to train log k models for bimolecular nucleophilic
substitution,181 bimolecular elimination, and different types of
cycloaddition.182 Similar approaches were used to develop
predictive models for the equilibrium constants of tautomeri-
zation reactions.183
Prediction of optimal reaction conditions
Since the reactivity of chemicals is largely determined by the
reaction conditions, their theoretical assessment is of particular
importance (especially for automated robotic synthesis). Several
approaches to reaction conditions modeling have been reported.
For example, Marcou et al.184 used CGR-derived fragment descrip-
tors to train SVM, RF, and Naive Bayes classification models to
predict optimal solvents and catalysts for the Michael reaction.
Gao et al.185 reported NN-based models trained on B10 million
reactions from Reaxys that identify appropriate catalysts, solvents,
reagents, and temperatures for a specified reactions. A 70%match
with experimental conditions was found within the top-10
predictions. Lin et al.160 used the heuristic that similar reactions
proceed under similar conditions to predict optimal reaction
conditions. They used a simple similarity search of reaction
databases with recorded conditions,160 especially effective with
the CGR technology.186 The value of this approach has been
demonstrated by protective group deprotection reactions.
Models trained on 142 111 catalytic hydrogenation reactions
demonstrated high accuracy (ca. 90%) for predicting optimal
experimental conditions.
In summary, the CGR technology can efficiently model
optimal reaction conditions. One employs similarity searching
of reaction databases to construct QSRR models, with reaction
conditions as endpoints. Studies summarized in this section
provide compelling examples of the impact of QSAR modeling
on one of the historically most empirical areas of natural
science, synthetic organic chemistry. The development of both
retrosynthetic and forward synthesis prediction models, based
on the analysis of an immense amount of accumulated data,
represents one of the most important frontiers in modern
science. It is essential for chemists to understand and begin
applying these emerging approaches. When coupled with
robotic synthesis methods, these synthesis prediction models
are poised to transform organic chemistry as we know it and
open the door to autonomous chemical synthesis systems in
the future.
Closed-loop discovery and automation
Traditional serial molecular and materials discovery processes
in laboratory have arguably reached a plateau. The costs of
discovering materials and drug candidates remain high and the
discovery and translation time is still long. Three decades ago,
combinatorial chemistry (also known as high-throughput
experimentation, HTE) promised to reinvigorate the discovery
pipeline by carrying out synthesis and experimentation rapidly,
in parallel using automation.187 HTE led to important discoveries
(such as novel polymers) and, indeed, has accelerated the dis-
covery pipeline. However, the avalanche of new drug leads that
was anticipated did not occur. More recently, DNA-econded
chemical libraries have made possible synthesis and testing of
millions of compounds188 and many big pharma companies have
embraced this approach.
Furthermore, there is a growing realization that experi-
mentation can be analyzed in terms of information theory.
Questions like what is the amount of information that an
experiment contains? What is the next best experiment to carry
out? can be answered by modern Bayesian methods. This
thinking has led to the revival of methods for developing
closed-loop or autonomous approaches. By closed-loop we
mean that the experimental system is designed using an
information-theoretical approach, and the experimentation
and assays are carried out in an automated way. By using
AI or evolutionary algorithms to make decisions on what
compounds to synthesize in the next cycle, in principle, an
autonomous system can be developed. The term ‘‘self-driving
laboratory’’ has been also coined to describe this type of
experimental setting.189 Clearly, a self-driving closed loop
laboratory is fundamentally different from existing HTE. The
closed-loop approach, designed to provide rapid iterations
using autonomous decision making, seeks to minimize the
number of experiments required to reach a specified goal
(e.g., target molecule(s)). It does not need to create large libraries,
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but rather employs agile experimental infrastructure, and statis-
tics and ML to build QSAR-like models to predict the target
properties for every element of the self-driving laboratory.190
Bayesian methods show promise for making closed-loop
decisions. Based on prior assumptions about the nature of
the experimental observations, they can propose the optimal
next experiment to conduct. PHOENICS,191 for example, employs
Bayesian neural networks and a kernel density estimate approxi-
mation to balance exploration vs. exploitation. Human interpret-
ability is also an important factor in these systems. The algorithm
chooses a set of experimental conditions to be generated by robot
synthesizers. It is not sufficient to understand what the system
generates; we must also know why certain recommendations
are made. Interpretability is clearly very important for modern
ML research. To aid interpretability, researchers have used
hierarchical optimization approaches that operate on one or more
variables. In multifactorial systems it is often necessary to under-
stand the pareto-optimal regions of the problem space. A mathe-
matical function called CHIMERA was recently introduced to
address these problems;192 it can be used with any optimizer,
such as PHOENICS.
Such systems require an operating system that is open-source
and capable of controlling experimental equipment, storing
data in databases, coupling with optimization approaches, and
interacting with researchers. A ‘‘Cortana-’’ or ‘‘Alexa-like’’ digital
assistant for scientists that is connected to the closed-loop system
could accelerate adoption and innovation. Efforts such as
ChemOS can help rally developers to achieve this vision.193
One of the promising applications of closed-loop discovery
is in the materials space. A recent review summarized the state-
of-the-art and challenges in this field.194 Examples of the
application of AI to materials discovery are described in this
review, as well as in following sections of this paper. One such
example is the design of blue emitters for organic light-emitting
diode devices accomplished by virtual screening of half
a million molecules.195 This approach led the successful dis-
covery of three lead candidate compounds with state-of-the-art
performance,195 exemplifying the promise of closed loop
discovery. The three good candidates required the synthesis
of only B40 materials. In autonomous systems, experimenta-
tion becomes the bottle neck in the accelerated discovery
process. This can be overcome by technological developments
– creation of self-driving, closed loop robotic laboratories
controlled by AI, as discussed in a recent perspective.196
Evolutionary algorithms can also be used to generate closed
loop, autonomous molecule and materials discovery system.
Their application to drug discovery and optimization, and
materials discovery have been reviewed recently.197 ML-based
QSAR can be used to model the fitness landscape of materials
experiments, which can substitute for downstream experiments,
improving efficiency and speed.
In summary, AI methods and models that optimally instruct
every step of robotic synthesis (including the choice of both
reagents and reaction conditions) represents a landmark in the
extension of QSAR methods toward dramatically more efficient
chemical synthesis.
Machine learning approaches in
quantum chemistry
Computational chemists, physicists, and biologists commonly
employ molecular potentials to evaluate energies and forces.
These are used to search for novel drug compounds and
materials. Hence, a faster but still accurate computational
method for evaluating molecular potentials is a very important
development. Potential applications include calculating the
free energy of protein–ligand binding via molecular dynamics
simulations, and the simulation of deformation dynamics in
materials.
The potential energies and forces provided by molecular
potentials are obtained traditionally by quantum mechanical
(QM) calculations or classical physics-based force fields (FF).
QM methods solve the Schro¨dinger equation and are the most
accurate methods for describing atomistic systems. The high
computation cost of QM and long-time scales relative to
experiment has limited studies of larger, realistic atomistic
systems. Hence, novel robust approaches approximating
QM methods without any loss in accuracy are required for
continued scientific progress. Force fields are computationally
efficient, allowing the simulation of up to millions of atoms,
but they require explicit parametrization of classical bonding,
angle, torsion, and possibly higher-order terms. The correct
parametrization of force fields can be tedious and cumber-
some. Further, parametrization for one atomistic system may
not be transferable to new systems.
Recent breakthroughs in the development of ML methods in
chemistry198 have produced general purpose models that pre-
dict potential energies and other molecular properties accu-
rately for a broad class of chemical systems. General purpose
models promise to make ML a viable alternative to classical
empirical potentials (EP) and force fields since EPs are known
to have many weaknesses, such as poor description of the
underlying physics, lack of transferability, and are hard to
systematically improve their accuracy.
Molecular representations
To develop a useful and efficient ML-based property predictor,
the most critical issue is how to represent the system in
question to a ML method. These representations (descriptors)
consist of some numerical representation of a molecule or a
system of atoms. There are a wide range of published descriptors
such as the Coulombmatrix,199 or its recent Bag of Bonds (BoB)200
extension. Other popular choices include descriptors that
represent molecular graphs,201 bonds and angles,202 many body
expansions,203 the atomistic local chemical environment,204 and
end to end models that learn the best description of the system
given minimal neighborhood information.205 Many of these
techniques have been successfully applied to either molecules
or materials.
Some recent descriptors like MBTR (many-body tensor
representation) and SOAP (smooth overlap of atomic positions)206
can describe both finite- and periodic systems. MBTR is derived
from the Coulomb matrix, BoB, and many-body expansion. SOAP
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kernel represents the local density of atoms within the environment
as a sum of Gaussian functions centered on each of the neighbors
of the central atom. It essentially defines the similarity between two
neighboring environments and uses it as a descriptor for ML
models.207
Local atomic environment vectors (AEV) are another widely
used molecular representation. AEV explicitly incudes all pairwise
combination of elements, which means that the size of the input
layer of a ML model grows as O(N2) with the number of included
chemical elements. Therefore, models can only be trained for
a relatively small number of chemical elements. Adding new
elements requires retraining the ML model again from scratch.
Recently, alternative weighting functions (wACSFs),208
circumventing the above issue, have been proposed. Though
this is a simple re-parametrization, the number of required
symmetry functions becomes independent of the actual number
of elements present in the system, leading to more compact
descriptors. This alternative solution to the growth problem was
introduced with the deep tensor neural network (DTNN)209 and
atom-in-molecule neural network (AIMNet). These constitute
learnable vectors of atomic features that are used to embed
atomic symmetry functions to make a unified representation of
each atom’s chemical environment. DTNN was subsequently
refined to create the SchNet architecture205 specifically designed
to model atomistic systems using continuous-filter convolutional
layers.
Neural network potentials
A ML approach applicable to chemical systems containing large
numbers of atoms, originally proposed by Behler and Parrinello
(BP method) in 2007, used high-dimensional neural network
potentials (NNP, Fig. 7).210 As in many conventional empirical
potentials, the potential energy E is the sum of local atomic
energies of all atoms in the system. Since this seminal publica-
tion, a substantial number of articles and reviews have been
published on the use of NNPs for bulk chemical systems
(e.g., bulk silicon or water) or for describing single molecule
potential energy surfaces and reaction coordinates.211
Recently, Smith et al. introduced the first NNP designed for
organic molecules, ANI-1.212 It is applicable to molecular
systems well outside its training set. The ANI-1 potential was
trained on a dataset of small organic molecules of up to 8-heavy
atoms (while sampling both conformational and configura-
tional space). Furthermore, ANI-1 demonstrated its applicabil-
ity to much larger systems, up to 70 atoms, including known
drugs and molecules randomly selected from the GDB-11213
database and containing up to 10 heavy atoms. It predicted DFT
energies of the test set molecules with up to 10 heavy atoms very
well, with the resulting RMSE values below 0.57 kcal mol1.
Many techniques for improving the accuracy and transfer-
ability of general-purpose ML potentials have been employed.
Among these, active learning methods, already proven successful
in conventional QSAR modeling, have been especially popular.214
Active learning methods provide a consistent and automated
improvement in accuracy and transferability and have contributed
greatly to the success of general-purpose models. An active
learning algorithm decides what new QM calculations should
be performed then adds the new data to the training set.
Allowing the ML algorithm to drive sampling improves the
transferability of an ML potential greatly. Further, transfer
learning methods allow the training of accurate ML potentials
by combining multiple QM approximations.
Fig. 7 Depiction of a standard feed-forward neural network potential for predicting a single property Ei from input G
-
i, computing the cost C with a cost
function, then back-propagated the gradient of the cost (with respect to the optimizable parameters) into the network for training.
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One fundamental limitation of BP-type models is the inability
to pass information between atoms at larger distances. Several
neural network architectures have been proposed to address this
limitation. The HIP-NN (hierarchically interacting particle neural
network) approach breaks molecules down into feature represen-
tations and uses a number for each atom and the pairwise
distances between atoms. On-site layers encode information
specific to each atom and interaction layers allow sharing of
information between nearby atoms. The total energy is built
hierarchically from those interactions.
Another architecture, SchNet, encompasses atom embeddings,
interaction refinements, and atom-wise energy contributions.
At each layer, the atomistic system is represented on atom-wise
basis and is refined by continuous filter convolutions with filter-
generating networks.215
In the AIMNet implementation, the solution to the short-
range problem is inspired by mean field theory (MFT). The
main idea of MFT is to replace all interactions of any one atom
with an average or effective interaction, sometimes called a
molecular field. This reduces any multi-body problem into an
effective one-body problem.
Datasets
As previously stated, one of the most important aspects of
building a model in chemistry is the choice of the training
dataset. Various datasets of organic and materials systems
for training ML models have been developed over the
last decades. Two of the most popular organic molecule bench-
mark sets are the QM7199 and QM9216 collections. The QM7
benchmark was developed by subsampling the GDB-13217
database of small molecules. QM7 contains 7165 energy-mini-
mized molecules consisting of up to 7 heavy atoms and several
properties computed with density functional theory (DFT). This
benchmark is difficult to model by ML because of its relatively
small size. Initial mean absolute errors (MAE), using the
coulomb matrix representation,199 were around 10 kcal mol1.
The ANI-1 dataset includes organic molecules with a large
number of non-equilibrium DFT total energy calculations.
It includes B24 M conformations for 57 462 molecules from
the GDB database, with the total energy values computed for
each conformation. This dataset samples both chemical and
conformational degrees of freedom at the same time and thus
provides 100more data. Therefore, we expect that this dataset
will become a new standard for comparing the ability of current
and future ML methods to improve on the best model accuracy
(1 kcal mol1) achieved for the QM9 benchmark. More impor-
tantly, this data source is a foundation for development of
future general-purpose machine-learned approaches.
The COMP6 benchmark dataset214 was developed to validate
the transferability of ML potentials. COMP6 is a benchmark
suite containing five rigorous benchmarks that cover broad
regions of organic and bio-chemical space of isolated molecules
and a sixth built from the existing S66x8218 noncovalent and
intermolecular interactions data.214 Properties are calculated
using the oB97x/6-31G(d) basis set, however, it could be recom-
puted using any desired quantum level of theory.
Advanced approaches
In addition to active learning, there are other ML techniques
that aim to reduce training data requirements. Some ML-based
methods (such as NN) can take advantage of information from
multiple sources. The key concept is to train a model using a
large dataset of medium accuracy, then retrain the model with
a smaller, more accurate and difficult to obtain data set. This
process called transfer learning (TL) relies on the assumption
that less accurate data sets contains some information that
makes it easier to learn models for the smaller datasets of
higher accuracy data.
For example, TL could be performed by taking a DL model
that was pretrained to medium-fidelity DFT, holding some
number of parameters in the model constant, then retraining
the remaining parameters using a much smaller, higher accu-
racy CCSD(T)/CBS dataset. Such methodology resulted in the
development of the ANI-1ccx potential, which represents an
attractive alternative to DFT and standard force fields for
conformational searches, molecular dynamics, and the calcula-
tion of reaction energies. The computed reaction energy values
demonstrated that the transfer learning-based ANI-1ccx
method outperforms DFT on test cases, especially those where
DFT fails to capture reaction thermochemistry.
In many systems, multiple data modalities can be used to
describe the same process. One such physical system is
the human brain, which provides more reliable information
processing based on multimodal information.219 Many ML
related fields of research have successfully applied multimodal
ML model training.
In chemistry, molecules, often represented by structural
descriptors, can also be described by accompanying properties
(dipole moments, partial atomic charges) and even electron
densities. Using multimodal information as inputs has been an
actively developing field in recent years.220 This boost is caused
by the use of additional information that captures the implicit
mapping between the learnable endpoints. We discussed the
advantages of multi-objective models over traditional single
task approaches in the sections on chemical safety prediction
and multi-target profiling above. Here we show that the same
approaches are equally useful for developing ML models of QM
results.
In the previous sections we have commented on the ongoing
revolution in organic chemistry brought about by advances
in computational (retro)synthetic approaches and robotic
chemistry. Similarly, the use of ML approaches in quantum
chemistry constitutes another recent paradigm shift. These
rapidly emerging approaches dramatically change current
limits of the size and complexity of molecular systems acces-
sible to QM-level structure and property calculations.
Materials informatics
Machine learning methods dependent on large experimental
and computational databases, are becoming ubiquitous tools
for materials development,221 extending their traditional use
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for organic molecules. Materials science is a very large field and
space constraints permit discussion of only a small set of
important questions and answers described below.
Which materials are missing?
This has been a perennial question,222 but several recent
studies have attempted to address this. For instance, Hautier
et al.223 used experimental data to create a probabilistic frame-
work for ionic substitution capable of dealing with sparse
spaces (quaternary configurations). ML has also been used to
tackle amorphous systems. For example, Perim et al.224 identi-
fied an energy spectral descriptor for de novo prediction of
metallic glasses and used it to quantify the classification
probability of mixtures. ML and atomic features (descriptors)
were also used to identify regions of compositions prone to
glass formation and demonstrated surprising accuracy.225
Descriptors, the Holy Grail of optimization: where can we find
them?
While the great importance of descriptors has been established,221
these parameters are often defined deus-ex-machina out of
intuition. Attempts have been made to develop interpretable para-
meterizations with ML. Thus, Ghiringhelli et al.226 proposed
compressive sensing to discover functional forms and tested
stability rules for binary semiconductors. Isayev et al.227 introduced
universal fragment descriptors for predicting properties of
inorganic crystal and developed electronic density of states and
band structure fingerprints that cluster many high temperature
superconductors (materials cartography). Recently, Stanev et al.228
identified 30+ non-cuprate and non-iron-based oxides, potential
new superconductors, using RF.
Can enthalpies (and other properties) be predicted?
The correct calculation of enthalpies and other properties is
important for ab initio computational materials design.229
Much progress has been made since the original principal
components analysis of alloy thermodynamics reported by
Curtarolo et al.230 Rupp et al.231 used kernel ridge regression
for modeling molecular atomization energies with mean abso-
lute error of B10 kcal mol1. In a related study, De et al.207
used the smooth overlap of atomic positions (SOAPs) to intro-
duce a very useful descriptor for comparing structures: the
‘‘alchemical similarity’’ for molecular and periodic structures.
Gaussian process regression (GPR) was used to generate very
accurate Gaussian atomic potentials (GAP) and then to train a
SOAP-GAP model within a ML framework (GPR) that achieved
a 99% accurate atomic-scale properties for Si surface recon-
struction, stability of molecules, and protein ligands.232 Pilania
et al.233 tackled melting temperatures of the octet subset of AB
solids and band gaps of double perovskites. De Jong et al.234
used statistical learning to study elastic moduli of inorganic
crystals, and with many other relevant studies.
What material properties can we predict?
Thermoelectrics. A lot of work has been performed for
computational predictions of thermoelectric systems following
the seminal paper of Madsen who proposed an automatic
search for new thermoelectric materials leading to LiZnSb.235
Legrain et al.236 developed a ML descriptor-based framework
(random forests and nonlinear support vector machines) and
found that chemical composition alone can reasonably predict
vibrational free energies. In the work of Carrete et al.,237
authors used classification trees to address nano-grained half-
Heuslers thermoelectrics.
Magnets. In Sanvito et al.,238 the ideal latent heat curvature
introduced in Yong et al.239 was calculated for all the Heusler
configurations of the AFLOW repository. This was performed
with the cloud phase diagram calculator by Oses et al.,240
leading to the discovery of two magnets Co2MnTi and Mn2PtPd,
the first ever discovered by computational means. Ko¨rner et al.
performed a ML high-throughput-screening of intermetallic
ThMn12-type phases and rare-earth-lean systems with YNi9In2-
type.241 Mo¨ller et al.242 built kernel-based ML models to opti-
mize chemical compositions for permanent magnets.
Light conversion and emission. To overcome input con-
straints of common ML pipelines, Duvenaud et al.243 developed
a convolutional neural network operating directly on graphs
(representing molecules of arbitrary size/shape), demonstrating
enhanced predictive performance over traditional fingerprinting
for solubility, drug efficacy, and organic photovoltaic efficiency
datasets. Go´mez-Bombarelli et al. integrated neural networks as
part of a larger computational discovery pipeline to prioritize
molecules for quantum simulations.195 This led to the discovery
of molecular organic light-emitting diodes with external quantum
efficiencies as large as 22%.
High-entropy systems. High-entropy materials continue to
attract research interest due to their remarkable properties, and
several semi-empirical methods have been proposed to predict
their existence.244 Most approaches use descriptors with para-
meters fitted to the limited experimental data. Modeling phase
diagrams with CALPHAD also suffers from insufficient experi-
mental knowledge.244 There was a recent attempt by Lederer et
al.245 to parameterize the miscibility-gap and solid-solution
boundary lines with ab initio calculations and statistical
modeling. Eventually, such analysis might mature into effective
ab initio descriptor-based characterization.
Other notable applications. Fernandez et al. proposed
an innovative QSPR model to recognize efficient metal organic
frameworks for CO2 capture. Emery et al.
246 performed a
descriptor based combinatorial analysis of perovskites for
thermochemical water splitting applications.
2D materials. Single or multiple layers of the same or
different 2D materials have exciting new electrical, optical,
heat transfer, and lubrication properties. Recently layers of
graphene have exhibited superconductivity.247 ML methods
have been used to predict the interlayer distance, band gap,
thermodynamic properties and superlubricity properties of
hybrid 2D materials.248
Welcoming new challenges!
Materials science properties, based on fundamental principles,
are intrinsically suitable for modeling by machine learning.
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Success in ML approaches is a driver for the discovery and/or
optimization of new materials and/or phenomena. This section
has given a short—unavoidably incomplete—snapshot of the
current state of the art.
What do our colleagues say about future frontiers? Jain et
al.249 identified challenges as follows: (i) streamlining the use
of large data resources (even with rational APIs, large databases
remain difficult to interrogate, especially when mixing data
from different repositories); (ii) developing descriptors for
crystalline, periodic solids; and (iii) balancing interpretability
(physical meaning) of descriptors versus accuracy of models.
The latter represents a well-known challenge resolved in
cheminformatics about a decade ago.250 Butler et al.198 added
the following extra challenges to this list: (iv) dealing with
smaller datasets (of critical importance especially for the
experimental world); (v) quantum learning (to enhance calcula-
tion speed); and (vi) establishing new principles (not only data,
but also laws, somewhat similar to Jain’s point about balancing
interpretability and accuracy).
What do we say about future frontiers? There is no need to
add further elements to the philosophical discussion of ML/AI’s
future. We should not underestimate the critical issues of
the following additional challenges: (vii) dealing with the dis-
ordered/amorphous systems (e.g., it is not a coincidence
that the field of high-entropy alloys is still lacking a compelling
ML work); (viii) sustainability and organization of big-data in
terms of computational infrastructure, standardization of data-
entries and prototypes, development of materials database
languages, e.g., AFLUX;251 (ix) further exploration of web-,
cloud-, and frameworks-directions, and the last but the most
important point (x) unless ML can generate new useful materials
faster than experiments alone, materials scientists’ interest in ML
will dissipate quickly.
To conclude this section, we highlight the clear similarity
between materials informatics with the traditional workflow of
QSAR modeling (see Fig. 1 and 8). As with cheminformatics, the
starting point of materials informatics is the accumulation of
large datasets of materials with experimental or computational
properties. The need for developing novel materials descriptors
and their use in building property prediction models using ML
techniques follows. Finally, current challenges outlined in the
concluding part of this section parallel many of those facing
traditional QSAR modeling of bioactive compounds. Thus,
materials informatics (and a closely related field of nanomaterials
informatics described in the next section) represents a prime
example of a new discipline, whose development was enabled and
immensely catalyzed by the experience and approaches developed
in QSAR.
Nanomaterials informatics
Nanotechnology is another field for which cheminformatics is
becoming a key tool, especially for the quantification of diverse
properties of nanomaterials and nanostructure–property
modeling. Development of modern AI algorithms has stimulated
Fig. 8 Machine learning materials flow is a combination of feature extraction, descriptor analysis, structure fingerprinting (representations) of databases,
and materials synthesizability. Figure reproduced with permission from the following sources: (i) ref. 240 Copyright (2020) American Chemical Society; (ii)
ref. 353 under the terms of the Creative Commons CC BY license; (iii) ref. 354 under the terms of the Creative Commons CC BY license; and (iv) ref. 355
Copyright (2020) by the American Physical Society.
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an increased interest in quantitative nanostructure–activity rela-
tionships (QNAR)252 also known as nano-QSAR. Like traditional
QSAR, QNAR models are based on the assumption that similar
nanomaterials will induce similar biological effects. However,
unlike QSAR, nanomaterials (and materials in general) are more
complex than single drug molecules, as they are less well defined
and feature distributions of sizes, shapes, etc.
QNAR models rely on an ensemble of molecular descriptors
that encode constitutional, topological, or geometrical charac-
teristics of a given set of nanomaterials. These descriptors are
derived directly from the structures of the nanomaterials using
bespoke software. Moreover, experimentally determined pro-
perties (e.g., elemental composition, zeta potential, size
distribution, shape) can also be appended to the computed
descriptors to boost the prediction performances of QNAR
models. This is analogous to the use of experimental HTS
results as descriptors to model biological endpoints for drug
candidates described in prior sections. QNAR models establish
quantitative relationships between those experimental and
computed descriptors and specified biological endpoints using
ML techniques.
Importantly, QNAR models are developed using the same
workflow (see Fig. 9), validation procedures, statistical criteria,
and key steps as those of classical QSAR models for small
molecules (see Fig. 1). However, the high structural diversity
and complexity of nanomaterials typically lead to specific
challenges,253 especially when it comes to the choice of mole-
cular descriptors. Two types of representations are clearly
emerging from the literature – studies in which the whole
nanoparticle is characterized computationally, experimentally,
or both or when such characterization is applied to the surface
chemistry of the nanoparticle (especially, organic decorators)
only. Naturally, the choice of descriptors and the associated
software is different for these two types of QNAR modeling. For
the second type of study the QNAR model is similar to a
traditional QSAR model, trained using descriptors for surface
chemistry, to predict biological activity of the nanomaterials.
Another challenge of QNAR modeling, similar to materials
informatics is the relatively small size of the datasets currently
available in the public domain. This leads to lower prediction
accuracy and smaller applicability domains for QNAR models
compared to those of QSAR models trained on large organic
molecule data sets. To mitigate this limitation, read-across
techniques are increasingly used to estimate the properties of
nanomaterials.254
Assessing the environmental impact of engineered nano-
materials (ENMs, see Fig. 10) requires data on their physico-
chemical and bioactivity properties, as well as bioaccumulation.
After data collection and validation, ML approaches can be used
to generate models correlating values of ENMs descriptors (e.g.,
structural, physicochemical, and bioaccumulation-related) and
specific toxicity outcomes associated with biological mechanisms
of action under various exposure scenarios.
The importance of data on ENMs structure and properties
Like other area of materials science, nanotechnology has
generated various datasets of physicochemical properties,
environmental fate and transport parameters, and bioactivity of
nanomaterials.255 They contain both literature curated and raw
data from various experimental investigations, useful for QNAR
modeling. For example, the OCHEM database255 contains
experimental data on ENMs and provision for generating
descriptors for model building, NanoMiner256 contains data
(including omics data) on 634 types of ENMs. The NM-bio-
logical interactions knowledge base contains over 200 toxico-
logical evaluations for embryonic zebrafish exposed to metal
Fig. 9 General scheme representing the development of quantitative nanostructure–activity relationships for the calculation of properties of
nanomaterials using both computed and experimentally determined molecular descriptors.
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and metal-oxide ENMs. NanoDatabank257 has raw data for over
1000 different nanomaterials and associated characterization
and toxicity data.
Early nanoinformatics efforts were focused on organizing
data into structured datasets (i.e., with fixed fields or records).39
However, there is growing recognition that significant data are
available as unstructured datasets (i.e., with no predefined fixed
fields or records), often are scattered across multiple literature
and online sources. Thus, significant recent efforts have been
devoted to the development of public databases, meta data, and
data management systems for nanomaterials. These efforts
included incorporation and integration of information from
multiple sources, addressing data security, effective data
sharing, intelligent data queries, and data integration.258 The
joint EU-US Nanoinformatics Roadmap 2030255 has stressed
the need for guidelines concerning the development of nano-
informatics datasets that are structured, have controlled ontology
for ENMs properties and bioactivity, and interoperability with
other databases and modeling tools. Raw data (free from pre-
processing by data curators) that can be curated and analyzed in a
context-dependent way are most useful for QNAR development.
Substantial amounts of experimental data on the toxicity of
ENMs have been generated, primarily in various cell lines such
as, macrophages, pancreatic and other human cells and
bacteria. There are still limited studies with simple organisms
like zebrafish and even fewer on higher animals. Toxicity data
include experimental results across multiple assays and cell
lines/types with ENMs having different surface modifications
and core compositions. There are different levels of confidence
and consistency across the toxicological studies. Currently,
efforts to derive generalized toxicity models based on ENMs
characteristics have been based on datasets from single studies
rather than integrated from the collective body of published
data.259 Clearly, to develop predictive nano-SAR models of
ENMs toxicity, it is useful to identify critical biological pathways
that can lead to adverse outcomes.260 Understanding relation-
ships between the structural and physicochemical properties of
ENMs and the biological responses and correlation between such
responses can be very useful for deriving causal relationships.
Although QNAR models provide valuable insight on ENMs
toxicity, they generally cannot provide direct mechanistic inter-
pretation that can be validated and tracked back directly to
experimental data. However, as with most other QSAR models,
ENMs toxicity models can be very useful in the absence of
mechanistic information or interpretation.
Clearly, to generate the most robust and predictive ENMs
toxicity models, the quality of data is paramount. These models
can then elucidate the relevance and significance of ENMs
properties such as structure, surface chemistry, shape and
other physicochemical parameters with respect to their biological
properties. Experimental conditions can also be employed as
independent variables when modeling toxicity. Several literature
studies have identified causal relationships between the biological
outcomes and important ENMs properties.261
Fig. 10 Nanoinformatics elements of environmental and health impact assessment for nanomaterials.
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QNAR modeling
Several seminal publications pioneered the field of QNAR
modeling. Puzyn et al.262 built the first nano-QSAR model based
on ensemble learning regression methods and CDK descriptors
to predict the cytotoxicity of 17 unique metal oxide nano-
particles. Fourches et al.263 introduced the concept of QNAR
modeling with a set of 109 functionalized CLIO nanoparticles
and their Paca2 cell uptake. This study has been repeated and
successfully reproduced several times by other research
groups.264 For instance, different series of metal oxides were
also modeled using the OCHEM webserver to generate reliable
QNAR models.265 Drug delivery properties of nanocarriers
could be successfully predicted by QNAR models as well.266
Important nanomaterials, carbon nanotubes, have had their
biological effects extensively modelled by QNAR. For instance,
Trinh et al.267 used a combination of computed and experi-
mental descriptors, encoded as quasi-SMILES, to build QNAR
models that could accurately estimate the cytotoxicity of carbon
nanotubes in human lung cells. Fourches et al.268 developed a
series of QNAR models for 83 functionalized CNTs tested
in vitro for protein binding and toxicity. These models reached
prediction accuracies up to 74% for external test set toxicity
estimates, and protein-binding classification models achieved
external prediction accuracies up to 77%. A library of 240 000
potential CNT surface modifiers was further screened using
these models and the least toxic organic modifiers were
selected for experimental validation. Subsequent synthesis
and testing of these surface-modified CNTs confirmed the in
silico predictions, demonstrating the utility of QNARmodels for
rational design of nanomaterials with enhanced properties.
In another study, a logistic regression-based QNAR model
was developed269 to flag toxic outcomes; this model was trained
on high-throughput toxicity screening data for BEAS2B cells
exposed to nine metal oxide nanoparticles. The best-performing
model had almost 100% classification accuracy and required only
three nanoparticle descriptors: the period of the nanoparticle
metal; the atomization energy of the metal oxide; and the
nanoparticle size and volume fraction. Another study used RF
classification to model cellular toxicity of metal oxide ENMs.270
The model was trained on data extracted from 216 publications,
and used 14 ENMs attributes as descriptors. It demonstrated
that cytotoxicity of ENMs was highly correlated with the admi-
nistered dose, assay type, exposure time, and surface area of
nanoparticles.270
Bayesian networks as models for predictive toxicology and for
assessment of causal relationships
Models that predict toxicity of ENMs must account not only for
the properties of the nanomaterials per se, but also for experi-
mental conditions (e.g., assay types, exposure concentrations,
exposure period, organism and more). It is important to
quantify the relevance and significance of ENMs and experimental
attributes driving toxicity while accounting for uncertainties in
data, particularly that collected from multiple sources. Toxicity
prediction models trained on these attribute combinations can
sometimes identify causal relationships,261 which can be effec-
tively achieved with the Bayesian network (BN, also called a
Bayesian belief network, BBN) approach.271
BN models construct a network where the modes are ENMs
characteristics and the edges (links) represent conditional
dependences of target outcomes on various attributes. This
provides a visual representation of causal relationships.272 The
model allows interpretation of ‘‘if/then’’ causal relationships
where the parent (antecedent) and child (descendent) nodes are
at the outgoing and incoming links in the BN structure,
respectively. The set of model attributes and their conditional
dependencies represents knowledge from the dataset(s) of
attributes and toxicity outcomes in the form of probability
distributions. BN models can identify, for example, the condi-
tional dependence that would lead to a toxicity outcome within
a specific range.
Previous studies have demonstrated the value of BNs for
developing qualitative ‘‘toxicity/hazard’’ classification of ENMs
based on using physicochemical and specialized descriptors.273
BN models identified the most relevant parameters impacting
specific ENMs hazards. Thus, regression and classification
models were developed274 for cause–effect relationships for
hazard associated with exposure to TiO2, SiO2, Ag, CeO2, and
ZnO NPs for different toxicity endpoints. A BN model predicted
the hazard associated with exposure to metal and metal oxide
NPs273 for eight toxicity endpoints compiled from 32 published
studies. Despite the existence of significant data gaps for some
NPs the resulting BN model identified the most relevant NP
properties for predicting toxicity outcomes.
Data variability and curation
As is true for traditional QSAR, inter- and intra-sample varia-
bility in QNAR is a big issue that can dramatically affect the
predictivity of a model. Therefore, in order to study and/or
model nanomaterials, the experimental variability for both
inter- and intra-sample measurements needs to be taken into
account whenever possible. For instance, the size distribution
of a given sample of a specified nanomaterial can vary from one
instrument to another. If a series of size distribution plots is
used to model a set of nanomaterials, then the experimental
variability of these measured profiles needs to be considered to
better understand the stability, reliability, and robustness of
the model. As with small molecule drugs and/or batches of
biologics, replicate measurements are necessary to understand
experimental variability. All, or a subset of compounds chosen
to be representative, and their associated samples are charac-
terized in triplicate. If one endpoint (e.g., particle diameter, zeta
potential) is deemed unreliable, that endpoint should not be
considered as a descriptor for those nanomaterials nor should
it be considered as a target property for a model. Clearly,
materials characteristics measured with low accuracy and
reproducibility, will limit the predictivity of the QNAR models
trained using them. Nanomaterials are particularly sensitive to
the protocols used for sample preparations (e.g., dilution,
sonication, solvent mixtures) leading to aggregation or even
degradation. Experimental variability is a general issue that the
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QSAR modeling field is constantly dealing with. Strict data
curation prior to model development is highly recommended,16
whereas external validation ensures the stability and robustness of
the models over all modeling and external prediction sets.
Perspectives
Although QNAR modeling is still in its infancy, we anticipate
it will grow significantly in the near future. This growth is
dependent on:
 development of more effective and interpretable ENMs-
specific descriptors
 further development of high-throughput synthesis and
screening platforms for nanomaterials, leading to the expan-
sion of publicly available data to train QNAR models
 development of more robust and predictive, consensus
models based on individual QNAR models trained on diverse
ENMs descriptors using advanced ML techniques including DL
 development of nanomaterials with desired properties
and pre-computed bioprofiles generated by interdisciplinary
research teams. The role of QNAR modeling in the context of
such multidisciplinary efforts cannot be overestimated.
Biomaterials and regenerative
medicine
Previous sections have covered major underlying concepts
of cheminformatics such as chemical similarity, QSAR model
building and validation, and domain of applicability. These
methods have been progressively extended to areas beyond
their traditional applications, for instance chemical genomics
and (nano)materials science as discussed above. Another emer-
ging field is the use of QSAR methods to model control of cell
phenotypes and understanding and predicting the biological
response to materials. These are relatively recent, but rapidly
expanding fields where the potential impact is very significant.
Unlike bioinformatics,275 cell biology, and clinical medicine,276
there is a relative paucity of published examples of the applica-
tion of QSAR or related ML-based methods to biomaterials,
regenerative medicine, and stem cells studies. Polymers and
other complex materials have been used in implantable or
indwelling devices, as replacement or augmentation of natural
bodily components, as scaffolds for cell culture, and as active
biomaterials and drug delivery systems. Unfortunately, such
materials are not as well defined as organic molecules.
As discussed above in the sections on (nano)materials infor-
matics, one of the biggest challenges in the field of biomaterials
is generation of appropriate descriptors that capture relevant
properties of these materials and can adequately represent their
structure, often poorly understood and characterized.20 In this
regard, rapid adoption of DL methods is providing useful models
for this very important issue.277 The feature generation capabi-
lities of DNN mean that simpler representations of complex
materials become possible. We further anticipate that predictive
material-QSARmodels may be interrogated to identify the types of
complex features that modulate relevant biological responses
most strongly.
Although the use of arcane molecular descriptors has
already resulted in good predictive models of the biological
effects of materials, there is increasing impatience with their
inability to be related back to underlying chemical features
interpretable by chemists to improve performance. The dilemma
between good predictions of properties for new materials, and
interpretability of models (mechanistically or in terms of mole-
cular interactions at a surface) has been reviewed recently by
Fujita andWinkler.20 This nexus has led to a rise in the popularity
of signature or fragment-based descriptors for modeling of
materials interaction with biological systems. For example,
signature descriptors have been used to model the adhesion of
bacteria to polymers.278 New MLmethods such as adversarial and
encoder-decoder networks have begun tackling the ‘inverse QSAR’
problem, where trained model can be used to design or suggest
new molecules for synthesis with improved activity.
A second important issue that distinguishes materials
modeling from small molecules modelling is that in the former
case interactions are more complex. Often materials interact
with mixtures of proteins, membranes, cells, and modulate the
responses of a myriad signal pathways, mechanosensors, etc.
Consequently, ML methods are best suited to address such
complexity and uncertainty, where the mechanisms of the
cell–materials interactions are largely unknown. Notably, ML
methods have been successfully used already for modeling soft
biological materials such as blood vessels.279
To date, QSAR methodology has been applied in regenera-
tive medicine and biomaterials modeling in three major groups
of studies. First, sparse and non-sparse feature selection
methods have been used to reduce the complexity of materials-
biological systems interactions. For example, sparse feature selec-
tion methods were applied to investigate stem cell behavior (see
Fig. 11 for details). Similarly, an expectation maximization algo-
rithm employing a sparse (Laplacian) prior59 was used to identify
the most relevant genes in unbiased genome-wide expression
studies. In one such study, mesenchymal stem cells (MSCs) were
exposed to the components of a biomaterial (strontium bioglass,
SrBG) with varying levels of strontium ions.280 These drive MSC
differentiation down the osteogenic pathway to form bone tissue.
After preliminary expression level and fold ratio filtering, the
sparse feature selection method identified a handful of genes
related to fatty and sterol biosynthesis – a previously unreported
mechanism of bone growth modulation. Subsequent experi-
mental validation of this mechanism by means of qPCR Raman
spectroscopy and protein expression profiling led to important
implications for the control osteoporosis and bone loss.
In another related investigation, unbiased sparse feature
selection methods were applied to gene expression data.281 In
this experiment, stem cells were forced to divide symmetrically
or asymmetrically in response to several types of experimental
conditions.281 Sparse feature selection methods were used to
identify robust markers for symmetric cell division, which is a
very important factor in stem cell proliferation and differentia-
tion studies.281
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/3
0/
20
20
 1
0:
15
:5
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2020 Chem. Soc. Rev., 2020, 49, 3525--3564 | 3551
ML methods have been increasingly applied to quantitative
modeling of the responses of biological systems to interactions
with materials.282 To date, most of these materials have been
polymers, due to their tunable properties, ease of library
generation and characterization, and generally understood
biocompatibility. Early work was conducted by the Kohn group
from Rutgers University who generated a library of 112 tyrosine-
derived polyarylates and measured a range of their physical
properties and biological responses.283 They used DRAGON
descriptors284 based on the monomeric units of the polymers
in combination with such parameters as glass transition tem-
perature (Tg) and air–water contact angle to generate quantita-
tive and predictive models of fetal rat lung fibroblast (FRLF)
metabolism and fibrinogen attachment on the polymer surfaces.
Subsequently, research teams at the University of Nottingham,
CSIRO, Monash University, and MIT generated polymer
microarrays285 and conducted high throughput screening to
elucidate structure–property relationships in their interactions
with cells.
The use of biomaterials as cell factories286 shows great promise,
and the large generated stem cell attachment, proliferation, and
differentiation datasets were modelled by ML methods. These
could make robust and accurate predictions of stem cell behavior
of materials not used to train the models. In one study, the
attachment of embryoid bodies (a surrogate and stable cell system
to mimic embryonic stem cells) to a polymer library was modelled
using sparse feature selection and optimally regularized neural
networks.287 These models relied on DRAGON descriptors and
Bayesian regularized neural networks to quantify the attachment
of embryoid bodies to the polyacrylate libraries. A more recent
study modelled attachment, proliferation, and differentiation of
human dental pulp stem cells to a polymer library.288 In this case
study, the authors also investigated the ability of a 541 members of
polyacrylate homopolymer and copolymer library to promote
attachment, proliferation, and differentiation of stem cells.
Finally, advanced QSAR methods are being applied to the
characterization of surfaces that interact with biological
systems and to analyzes of complex high-content data such
as cell imaging and phonotype recognition. Surface analysis
methods such as Raman and Time-of-Flight Secondary Ion
Mass Spectrometry (ToF-SIMS) are invaluable experimental
tools for characterizing the nature of surfaces interacting with
biology. Surprisingly, there has been little application of statis-
tical methods and ML to the corresponding spectroscopic data.
ToF-SIMS in particular has proven to generate data that is very
useful for QSPR material modeling.285 Recent work has shown
how self-organizing maps (SOMS) can provide superior clustering
of complex mass peak data,289 probing into the intrinsic infor-
mation content (Shannon entropy) of these surface analysis
methods.290
As the field of biomaterials modeling is relatively nascent,
there are many issues that need resolving before the full benefit
of AI/ML-based QSAR methods can be realized. The most
important of these issues is how to represent a high molecular
weight complex material such as a cross-linked polymer hydro-
gel or polymer library with distributions of chain length, block
sizes, degree of cross-linking, etc. Although surprisingly effec-
tive models can be generated using descriptors based on small
fragments, additional materials features may be needed where
these approximations fail. More recently methods have been
developed that allow many types of nanoscale topographies to
be imprinted onto materials surfaces. These modulate bio-
logical properties such as macrophage polarization, so efficient
ways of generating descriptors for topographical features are
required. Equally important is the need to generate models
that can be interrogated to guide the synthesis of subsequent
generations of materials with improved characteristics.197
Biological data variability and reproducibility are also a constant
struggle for high throughput materials-based experiments.
Improving the reliability of these biological response data by
careful statistical treatment of results and improved fabrication
quality control is also important. However, as modeling of
biomaterials coevolves with further development of the respec-
tive experimental research, one shall expect models to become
more robust and impactful.
Clinical and health informatics
Just as advances in statistics, ML, and AI have influenced
chemical research, experience accumulated in cheminformatics
can be applied to clinical research. The growing linkage
between QSAR modeling and clinical informatics was high-
lighted by the most recent 22nd EuroQSAR meeting in 2018
dedicated explicitly to ‘‘Translational and Health Informatics:
Implications for Drug Discovery’’.291 One example of such
cross-fertilization between the fields is the development of
Fig. 11 Changes in hMSC global mRNA expression mediated by treatment
with BG- and SrBG-conditioned media. (A) Operation of the EM algorithm,
showing progressive nulling of lower genes less relevant to the SrBG
treatment. (B) The contribution (mean  SE) of the most significant genes
identified by sparse feature analysis. (C) Functional annotation clustering
analysis of differentially expressed genes in response to Sr100 treatment
compared with control. Figure is reproduced from ref. 280 with permis-
sion from Proceedings of the National Academy of Sciences of the United
States of America.
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robotic biomarkers of motor impairment of patients recovering
from stroke.292
One of the greatest challenges in designing clinical trials is
dealing with the subjectivity and variability introduced by
human assessment of clinical endpoints. This problem is
particularly acute in neurology, where outcomes may be highly
variable (e.g., in cognition), susceptible to the state of the
patient (e.g., fatigue, pain, anxiety, depression), the lack of a
gold standard definition or diagnosis (e.g., neuropathy, demen-
tia), are high dimensional (e.g., imaging or genomic markers),
or are composite in nature (e.g., clinical instruments for
assessing depression or quality of life).293 These factors
make it difficult to demonstrate treatment benefits, requiring
larger pools of subjects in clinical trials as well as properly
structured electronic health record (EMR) archiving and retrieval
capabilities.
Neurological disorders such as stroke suffer from clinical
assessment limitations as established methods are often
subjective: scales such as the Fugl-Meyer (FM),294 motor power
(MP),295 NIH stroke (NIH),296 and modified Rankin (MR),297
require properly trained personnel for evaluation, with results
widely varying from rater to rater.298 While extensive training of
raters and centralization of outcome assessments (whenever
possible) can reduce variability, it does not completely elimi-
nate it and comes with its own additional costs.299
One way to minimize this measurement variability issue
is to replace human raters with robotic technology that can
provide repeatable, reliable and speedy assessment of contin-
uous measures of impairment and its change during recovery.
Robotic devices are less sensitive to the skills and expertise of a
human rater, can reduce inter- and intra-rater variability, can
be used simultaneously for both assessment and rehabilitation,
which can be done faster and more frequently, and can further
be used in a home setting thus minimizing patient burden and
inconvenience.299
The following study illustrates the use of QSAR-type appro-
aches in clinical informatics. To test their utility in clinical
trials, the four clinical scales mentioned above were used in
conjunction with a robotic assay to measure arm movement in
208 patients at 7, 14, 21, 30, and 90 day time-points after acute
ischemic stroke. The data were collected at two clinical sites in
the US and the UK. The study had two goals. The first was to
establish whether the robotic measurements could predict the
scores of human raters, and the second was to develop a more
sensitive robotic biomarker that could reduce the sample size
of the study without compromising the predictive value. The
robots were low impedance and low friction interactive devices
that measured speed, position, and force.300 The robotic assess-
ment consisted of 35 macro- and micro-metrics derived from
various directed, unassisted reaching, circle drawing, resis-
tance to external forces, and shoulder strength measurements,
applied to the affected and unaffected arms.301
The relationships between these 35 robotic variables and the
four clinical scales were visualized (see Fig. 12) using stochastic
proximity embedding (SPE), a self-organizing nonlinear mapping
algorithm that was originally invented to visualize very large
combinatorial chemical libraries135 and subsequently adapted
for various molecular modeling applications.302 Having estab-
lished a degree of correlation, models were generated to assess
whether the robotic metrics could predict the clinical scales
with sufficient accuracy to serve as their surrogates. The model
was trained using the data from degree of recovery from day 7
to day 90 after stroke, and all other intermediate measurements
were used as test data. Specifically, 208 patients were divided
into two complementary populations: those with complete data
sets for days 7 and 90 (referred to as completers; N = 87) and;
those with missing data on days 7 or 90 (referred to as non-
completers; N = 121). The models, based on feed-forward NNs,
were derived independently for each clinical scale. They were
trained to predict the clinical scores of a given patient on a
given day from the respective robotic metrics, using the com-
pleter population as a training set.
To minimize over-fitting, a feature selection algorithm based
on artificial ant colonies, originally developed for QSAR appli-
cations, was used to identify the subset of robotic metrics that
had the highest predictive power.303 Once the relevant features
were identified, ensemble models comprising 10 neural
network predictors were constructed using the same network
topology and training parameters but initialized with a different
random number seed. The predictions of these models were
averaged to produce an ensemble prediction. All models were
cross-validated using the standard jackknife approach that
divided the training data into 10 disjoint subsets containing
10% of the patterns each, systematically removing each subset
from the training set, building a model with the remaining
patterns, and predicting the clinical scores of the removed
patterns using the optimized network parameters. The resulting
predictions were compared to the original clinical scores to
evaluate the overall agreement with the RCV
2 metrics. This process
was repeated 10 times to obtain more robust cross-validation
statistics. Finally, the best models identified by cross-validation
were used to predict performance of the non-completers, who
formed an independent test set. This protocol was virtually
identical to the one used for QSAR applications.304
The resulting models recapitulated the human scored
clinical scales with a cross-validated R2 of 0.73, 0.75, 0.63,
and 0.60 for the FM, MP, NIH and MR scales, respectively.
The models also showed lower but still useful predictive power
for the external validation set (non-completers). The models
had better prediction accuracy for the FM and MP scales that
are more closely related to motor function than the NIH and
MR metrics. Finally, the models were used to derive novel
composite robotic endpoints with improved sensitivity (and
effect size) compared to existing scales. To measure the effect
size, Cohen’s d parameter for paired observations was used,
defined as the mean divided by the standard deviation of
the day 7 to day 90 changes over all the completers. Since
optimizing nonlinear composites is an ill-posed mathematical
problem, a greedy forward-selection algorithm was employed to
select up to 8 most relevant robotic features. Optimized robotic
composites with as few as four features increased the effect size
over a reference natural history trial305 by as much as 107% for
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the training and 83% for the test set. This result is highly
significant as an increase of 83% in effect size would result in a
70% reduction in the number of patients required to achieve
the typical 80% statistical power in a clinical trial.
While the primary purpose of EMRs is to serve patient care,
the second QSAR-inspired study illustrates how structured EMR
information can be processed with unsupervised learning to
improve patient phenotyping in chronic obstructive pulmonary
disease (COPD).306 COPD, a heterogeneous disease charac-
terized by persistent, non-reversible airflow limitation is the
fourth leading cause of death in the United States (as of 2010).
While ‘‘phenotype’’ is a co-emergent property of the genotype–
environment interaction, COPD has been classically stratified
in two phenotypes,307 the ‘‘blue bloater’’, which is rooted in
chronic bronchitis (cyanosis due to hypoxemia), and the ‘‘pink
puffer’’, which is rooted in emphysema (pink skin and hyper-
inflation), although up to seven COPD phenotypes have been
proposed, based on ‘‘clinical relevance’’.308 Unsupervised learn-
ing was used to analyze EMR data from COPD patients, first to
find out if common COPD patterns exist, which in turn could
identify different COPD subtypes and lead to improved thera-
peutic management within each COPD subtype. A total of 3144
patients aged 40 or older, admitted to the University of New
Mexico Hospital, a 580-bed tertiary hospital with a COPD
diagnosis (ICD9 codes: 490, 491, 492 or 496) between 1 January
2011 and 1May 2014 were processed for this study. Data processed
Fig. 12 SPE map of the correlation distances of the clinical and robotic parameters for the completers cohort. The map was derived by computing the
pairwise Pearson correlation coefficients (R) for all pairs of features, converting them to correlation distances (1  abs(R)), and embedding the resulting
matrix into 2 dimensions in such a way that the distances of the points on the map approximate as closely as possible the correlation distances of the
respective features. The clinical parameters are highlighted in red, the robotic parameters on the affected side in blue, and the robotic parameters on the
unaffected side in green. The map also shows distinct clusters of correlated variables which are preserved on both the affected and unaffected sides
(outlined by green and blue ellipses, respectively).
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/3
0/
20
20
 1
0:
15
:5
6 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
3554 | Chem. Soc. Rev., 2020, 49, 3525--3564 This journal is©The Royal Society of Chemistry 2020
in this analysis included demographics, comorbidities, presence
of atopy, obesity, number of admissions, prescriptions for
inhalers (grouped as: (i) short acting beta-agonist, (ii) long-acting
beta-agonist, (iii) anticholinergics, (iv) steroids and (v) combina-
tions), prescriptions for oral steroids, beta-blockers and statins,
as well as weight loss and elevated plasma bicarbonate (used
as surrogate biomarkers for disease severity). All variables,
including age (40–65 years and 465 years) and number of
admissions (one admission andZtwo admissions), were coded
as binary for the study.
These data were clustered using the sphere exclusion
algorithm,309 a disjoint similarity method that has been widely
applied in cheminformatics. In the disjoint similarity method,
a patient (object) can belong to only one cluster.310 When
processing this multidimensional space that has as many
dimensions as variables, dissimilarity can serve as the distance
metric between patients. By definition, similarity is set to 0 if all
the variables are different and is set to 1 if they are equal.310
As described elsewhere, in sphere exclusion the only user input
is the similarity threshold: first, the similarity between all
patients was computed. The algorithm then identified the
patient with the most ‘‘neighbors’’ within a specified similarity
cut-off, forming the first cluster. These patients were excluded
from further iterations. The process was repeated until only
patients without neighbors (i.e., singletons) were left. For this
dataset, the optimal balance between the number of clusters
and clustering overlap was found at similarity threshold 0.62.
Using the sphere exclusion algorithm for clustering reduces the
risk of bias since the method does not make a priori assump-
tions regarding numbers of clusters or similarity thresholds.
After leaving 189 patients (6%) as outliers, the following
nine COPD clusters (phenotypes) were identified, with the
number of patients given in brackets: 1: depression-COPD
(1748); 2: malignancy-COPD (312); 3: coronary artery disease-COPD
(291); 4: young age-low comorbidity-high readmission-COPD
(152); 5: advanced malignancy-COPD (144); 6: cerebrovascular
disease-COPD (120); 7: atopy-COPD (81); 8: diabetes mellitus-
chronic kidney disease-COPD (64) and 9: advanced disease-
COPD (43). The largest cluster is characterized by a large
proportion of patients over age 65 and depression; two clusters
(2 and 5) are associated with malignancy, although the first one
has few readmissions whereas the second one has signs of
advanced COPD and frequent readmissions. Cluster 3 is asso-
ciated with heart disease (patients over age 65), whereas cluster
6 is associated with predominantly cerebrovascular disease
and younger (under 65) patients. Cluster 4 (young patients,
few comorbidities) has the highest number of prescriptions for
bronchodilators; cluster 7 is also comprised of patients below
age 65, but with asthma/atopy and higher numbers of read-
missions; cluster 8 is associated with chronic kidney disease
(CKD) and type 2 diabetes in patients aged 40–65, whereas
cluster 9 has frequent readmissions, severe disease and high
number of anticholinergic prescriptions. Our analysis revealed
five previously unreported COPD phenotypes: two malignancy-
COPD clusters (2 and 5), the COPD-CKD-diabetes cluster (8),
the ‘‘advanced disease’’ cluster (9) and the high readmission
phenotype (4). Each of these new clusters has practical
implications, which may lead to better therapeutic outcomes.
To summarize, the above studies successfully adapted
methods from computational chemistry and cheminformatics
into in-depth analyses of health data. We anticipate that this
transfer of methods and experience will continue to fuel health-
care informatics research by introducing new and improved
computational methodologies.
Outlook
The field of QSAR modeling based on simple approaches used
to predict chemical reactivity was initially popularized by
Corwin Hansch and his colleagues more than 55 years ago.1
For many years, even decades, this field was focused on the
prediction of physicochemical properties and biological activities
using descriptors representing intrinsic properties of chemical
structures. However, as the size and diversity of chemical datasets
expanded, the QSAR modeling field has evolved to include larger
and more diverse types of chemical descriptors and increasingly
more complex statistical and machine learning techniques.
We reflected on these trends earlier,2 and foreshadowed the
impact that these developments in the QSARmodeling community
would have on many other areas of research. We projected that,
with the continuing strong growth of publicly accessible data, this
field will become essential for extracting knowledge from, and
making predictions with, these massive data sets. We forecast that
the field will continue to embrace even more powerful and
complex machine learning methods. Furthermore, we expect that
these modeling methods will continue to find rapid acceptance
not only in chemistry but also in new fields beyond chemistry,
where large data sets are readily available and modeling complex
relationships between a set of independent variables and given
properties of interest are important. The recent expansion of QSAR
studies using DL approaches (as discussed in the section on
modern trends in QSAR) is an early harbinger of these
expectations.
We have illustrated some of non-traditional applications
in this review, demonstrating how QSAR-like approaches are
beginning to yield exciting results in research areas as diverse
as quantum mechanics, materials and nanomaterials science,
biomaterials, regenerative medicine, and health care. Impressively,
many of the roadblocks and technical issues in statistical data
modelling employed in different domains of knowledge had
already been addressed in the QSAR modeling literature. Examples
include papers on the impact of the errors on QSAR analysis311 and
the importance of data curation to achieve stable and reproducible
models.16 These considerations were under active discussion in the
QSAR community before the reproducibility crisis brought to light
by the NIH312 and biomedical scientific community at large.313
Similarly, rigorous model validation prior to prediction15 and the
importance of rigor in modeling protocols314 have been articulated
in several seminal publications in QSAR field315 and have already
been adopted as regulatory requirements.99 Extreme examples of
the application of QSAR concepts beyond its traditional domain are
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provided by a study into factors influencing temporal crime
patterns in Chicago316 that cites a well-known work on QSAR
model validation315 and a study on stock price predictions.317
We expect QSAR-like modeling techniques to continue to
expand substantially even beyond the areas where it is starting
to make an impact, which we discussed above. Scientists
working in this field will continue to experiment with novel
statistical, machine learning, and AI algorithms to accelerate
the experimental discovery of novel compounds and materials
with desired properties. The jury is still out on whether the
newest DL approaches will improve the prediction accuracy of
QSAR models. However, we expect that the answer will emerge
in the next few years, given the tremendous activity in this field.
As discussed above, stunning and potentially paradigm
shifting developments are occurring in the use of machine
learning approaches to massively accelerate quantum mechan-
ical calculations, without sacrificing accuracy, and the use of
QSAR methods for de novo compound design. Another fascina-
ting and emerging direction is AI-driven chemical synthesis
route prediction and its synergy with robotic synthesis, also
discussed above. We anticipate amultitude of new and interesting
algorithmic developments in the area of retro- and forward
synthesis design, with software integrated with the robotic
systems. We should soon see the emergence of fully autonomous,
‘close loop’ chemical and materials synthesis and optimization
systems. In addition to these methodological developments, we
foresee many new and impactful experimental methods arising
that lead to novel, useful, and safe chemicals when QSAR
modeling is applied to these data, and the increased application
of ML methodologies in drug target selection, gene–phenotype
evaluation and disease modeling. Finally, besides potentially
exciting developments in traditional areas of application in
chemical sciences, we further expect that the experience in model
development, validation, and exploitation of QSAR models for
knowledge discovery in chemical sciences will lead to progressive
expansion of QSAR modeling principles and approaches in many
other disciplines.
Conclusions
This contribution was conceived by a group of scientists who
have dedicated significant portions of their professional careers
to the development and use of quantitative methods in com-
putational chemistry and molecular modeling. Following the
previous highly cited comprehensive survey of QSAR modeling
that was coauthored by many contributors to this paper and
published in 2014,2 we felt it was time to reflect on the new and
exciting developments in QSAR modeling that have emerged in
the last five years due to proliferation of large and diverse
(Big Data) molecular bioactivity datasets and of burgeoning use
of associated Big Data analytical methods such as DL. We also
intended to share our observations and excitement concerning
the prolific use of similar ML approaches in areas beyond
chemical domain; the latter excitement and observations were
in part influenced by the transition to other fields that some
original cheminformaticians, including several co-authors of
this paper, have made in their own research evolution and
career development. Herein, we have summarized recent and
developing trends in several areas of research where statistical
data modeling has begun taking a prominent place and where
experiences and generalizable approaches of QSAR modeling
could catalyze new discoveries. We hope that this collective
contribution will be useful for both specialists in data modeling
and experimental researchers looking to expand their toolkits
to include computational data analytical approaches.
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